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Theromin, a novel thrombin inhibitor from the leech Theromyzon tessulatum,
has been shown to be the strongest inhibitor to date. There has been a lot of attention

on direct thrombin inhibitors as a much more efficient drug for anticoagulation
therapy. One main reason for the need of strong direct thrombin inhibitors is that the
current therapy, heparin, causes alternative clotting events in some patients where
antibodies are made to the heparin/thrombin complex and causes clots to occur by
different methods. Recently there has been a strong inhibitor from a leech used,

hirudin, that can inhibit with a K, of 21 fM. This is the strongest inhibitor currently
used as a therapy for patients suffering from clotting issues. This work investigated a

leech inhibitor that has a K¿ of 13 fM making it an even better candidate for therapies
as it will inhibit more efficiently.
Copper is scrupulously regulated within the cell to maintain proper balance of
redox activity and storage. One protein involved in this process is Wilson disease
protein, which is responsible for moving copper into vesicles for either storage or
removal from the cell. Previous work has shown copper is transferred to the Wilson
disease protein via its metallochaperone, HAHl. The proposed mechanism for this
transfer seems to involve a transient 3-coordinate copper(I) intermediate. Similar

work done on Saccharomyces cerevisiae has shown that a 3 -coordinate intermediate

could exist between Atxl (analogue of HAHl) and its partner Ccc2. Trapping this
intermediate involved selective mutation of individual cysteines involved in the
copper(I) binding.

UMI Number: 3440825

All rights reserved
INFORMATION TO ALL USERS

The quality of this reproduction is dependent upon the quality of the copy submitted.
In the unlikely event that the author did not send a complete manuscript
and there are missing pages, these will be noted. Also, if material had to be removed,
a note will indicate the deletion.

UMI
Dissertation Publishing
UMI 3440825

Copyright 2011 by ProQuest LLC.
All rights reserved. This edition of the work is protected against
unauthorized copying under Title 17, United States Code.

ProOuesf

®

ProQuest LLC

789 East Eisenhower Parkway
P.O. Box 1346

Ann Arbor, Ml 48106-1346

Copyright by

Brian A. Zeider
2010

ACKNOWLEDGMENTS

I would like to graciously thank Dr. David Huffman for his support, guidance,
and opportunities to not only work in his lab, but also other opportunities such as
studying NMR at CERM in Florence, Italy and attending the International Conference
for Biological Inorganic Chemistry (ICBIC 14) in Nagoya, Japan. I would also like to
thank my other committee members: Dr. Ekkhard Sinn, Dr. Susan Stapleton, and Dr.
Thomas Thamman for their support and suggestions throughout my time at Western
Michigan University. Finally, I'd like to thank Dr. Ivano Bertini for allowing me the
opportunity to visit CERM, and Dr. Simone Ciofi and Dr. Francesca Cantini for their

help in teaching me some of the techniques involved in protein NMR and providing
housing and a fellowship while I was there, and the Huffman group for their help and
suggestions throughout my time at WMU. Overall, I'd like to thank the Chemistry
Department at Western Michigan University and Western Michigan University itself
for giving me the opportunity to attend and receive my Ph.D.
Brian A. Zeider

ii

TABLE OF CONTENTS

ACKNOWLEDGMENTS

p

LISTOFTABLES

viii

LIST OF FIGURES

x

LISTOFABBREVIATIONS

xiii

CHAPTER

1.

BLOOD CLOTTING MECHANISMS AND INHIBITION

1.1

1.2

Blood Clotting Cascade

1

2

1.1.1

Extrinsic Pathway

3

1.1.2

Intrinsic Pathway

3

1.1.3

Clot Formation

5

a-Thrombin

1.2.1

6

Proteolytically Cleaved Forms of a-Thrombin
1.2.1.1

a-Thrombin

7
8

1.2.1.1.1

a-Thrombin Exosites

8

1.2.1.1.2

Sodium Binding

10

1.2.1.1.3

a-Thrombin Acitve Site

14

1.2.1.1.4

a-Thrombin Functionality

14

1.3

a-Thrombin Inhibitors

16

1.4

Hirudin

18

1.5

Theromin

22

1.6

Physiological Significance of Theromin

23

iii

Table of Contents—continued

CHAPTER

2.

1.7

Objectives of This Study

23

1.8

References

25

COPPER TRAFFICKING PATHWAYS

2.1

Importance of Copper in Cells

35

2.2

Copper Movement Through Cells

35

2.2.1

2.2.2

Ctrl Proteins

38

Copper Chaperone for Wilson Disease Protein
(HAHl)

2.2.2.1
2.2.3

43

Human Atoxl: (HAHl)

2.2.3.1
2.3

43

Wilson Disease Protein and Interactions with

Cu(I)HAHl

3.

34

46

Wilson Disease Protein (WLNP)

References

47
56

MATERIALS AND EXPERIMENTAL METHODS

63

3.1

Listing of Chemicals, Reagents, and Peptides

64

3.2

Protein Production and Biochemical Studies

70

3.2.1
3.2.2

Theromin Transformation, Expression, and

Purification

70

Inhibition Characterization

75

3.2.2.1

3.2.3

Theromin Inhibition Kinetics

Wilson Disease Protein Domain 4 Transformation,
Expression, and Purification

iv

75

77

Table of Contents—continued

CHAPTER

3.2.4 13C15N Double Labeled Cysteine WLN4,

Transformation Expression, and Purification

3.2.5

N WLN4 Transformation, Expression, and
Purification

84

3.2.6 15N and Native Isotope HAHl Transformation,
3.2.7

3.2.8

3.3
4.

80

Expression, and Purification

84

NMR Studies of the Intermediate Interaction
Between WLN4 and HAHl

86

UV-Vis Titrations of WLN4-HAH1 Intermediate
Interaction

88

3.2.9 HAHl 199Hg(II)NMR

90

3.2.10 199mHg(II) Perturbed Angular Correlation (PAC)

91

3.2.1 1

93

Hg(II)HAHl Aggregation State by Gel Filtration

References

98

BIOCHEMICAL PROPERTIES OF THEROMIN: A NOVEL

THROMBIN INHIBITOR

100

4.1

Introduction

100

4.2

Recombinant Expression of Theromin

102

4.3

Theromin Inhibition Kinetics Toward a-Thrombin

103

4.4

Copper Binding Studies

108

4.5

Conclusion

111

4.6

Future Studies

1 12

4.7

References

115
?

Table of Contents—continued

CHAPTER

5.

THE INTERACTION OF WILSON DISEASE PROTEIN METAL-

BINDING DOMAIN 4 WITH HAHl
5.1

5.2
5.3

118

Wilson Disease Protein Domain 4 Expression and
Purification

121

HAHl Expression and Purification

123

5.4 NMR Titrations ofWLN4 with HAHl and Copper(I)

124

5.5

NMR Technique to Investigate Protein Interactions

131

5.6

Yeast Homolog System: Atxl/Ccc2a

132

5.7

6.

Introduction

118

UV-Vis Titrations of WLN4:HAH1 Interaction in the

Presence of Copper(I)

134

5.8

Conclusion

146

5.9

References

149

BIOPHYSICAL CHARACTERIZATION OF MERCURY(II) HAHl
USING PERTURBED ANGULAR CORRELATION, MERCURY(II)199 NMR, AND GEL FILTRATION STUDIES

152

6.1

Introduction

152

6.2

Mercury(II)-199 NMR

155

6.3 199mHg(II) Perturbed Angular Correlation

156

6.4

Aggregation State Studies Based on pH Titrations Using
Gel Filtration Analysis

162

6.5

Conclusion

164

6.6

Significance of Study

166
vi

Table of Contents—continued

CHAPTER

6.7

References

167

VITA

170

vii

LIST OF TABLES

1 . 1 Relative ratios of anionic character vs. hydrophobic character to
describe the selectivity characteristics between the two

1 .2 A list of different expression systems tried as hosts for over expression
of rHirudin

2.1 Tabulated values for copper affinities for the different metal-binding
domains of Wilson disease protein and its copper chaperone, HAHl

3.1 List of proteins and their respective vectors, tags, and proteases

11
21

50
64

3.2 Reagents, manufacturers, and purities (where available) used in the
following experiments

64

3.3 List of biological reagents used in the following experiments

67

3.4 Listing of instrumentation used for experiments

68

3.5 GE Life Sciences AKTA FPLC columns

69

3.6 Theromin inhibition kinetics set-up parameters, all components were
made as stocks in the assay buffer

77

3.7 Recipe for M9 minimal media used in growing cells capable of

incorporating 13C,15N-L-cysteine into their proteins

3.8 Buffer composition for each pH of the Hg(II)HAHl gel filtration studies

83
94

3.9 List of calibration standards used on the HRl 0/30 gel filtration column

to determine apparent molecular weights of the different aggregation
states of apo and Hg(II)HAHl

96

5.1 The NMR experiments used to monitor the titration using 1H and 1H
15NHSQC

125

5.2 Typical delay times used to determine the relaxation rates

130

5.3 Compilation of the tumbling times for the different titrations done

131

5.4 EXAFS fit results

145
viii

List of Tables—continued

6.1 Parameters fitted to the PAC-data

159

6.2 Calculated partial NQI for Hg(II)HAHl

160

6.3 NQFs parameters calculated from the X-ray structure

160

6.4 Compilation of the elution volumes and apparent masses OfHg(II)HAHl
at the various pH values

ix

162

LIST OF FIGURES

1.1 Illustration ofthe blood clotting cascade

1.2 Thrombin surfaces describing the electrostatic and hydrophobic regions,
as well as where fibrinogen fits into the structure

1.3 Thrombin makes some extensive allosteric changes upon binding of
sodium

1.4 A cartoon describing the anticoagulant abilities of a-thrombin as it binds
to thrombomodulin, and activates protein C

1.5 Charged Surface map of rHirudin (desulfonated tyrosine 63). This is a
stereo view each being 180° from each other

1 .6 Hirudin, the blue sticks, is shown bound to thrombin

2.1 Chemical equations illustrating how copper(I) can disproportionate into
the highly oxidative copper(II) and further undergo the Fenton reaction
to make a highly reactive hydroxide radical

2.2 Illustration describing the different fates for copper

2.3 Predicted 2D representations of different types ofproteins that move
things across membranes

1
6

13
15
18

19

34
36
38

2.4 A dimer of trimers showing the Ctrl as it spans the membrane.

39

2.5 A and B show helix alignment of the helices that compose Ctrl

40

2.6 Cartoon representation of the Ctrl

42

2.7 Model of CuHAHl depicting the copper bound to the two cysteines of
HAHl

2.8 Model of the Hg(II)HAHl homodimer determined by X-ray
crystallography

?

45
46

List of Figures—continued

3.1 Amino acid sequence of theromin, the orange residues constitute the
negatively charged region of the peptide that is presumed to bind to the
exosites

71

3.2 Purification and cleavage of GST-Theromin
3.3 A typical plot used to determine a K01, value that corresponds to an
apparent molecular weight

4.1 SDS-PAGE of theromin after 16 hours of cutting
4.2 The slope of the line is the Ki>app, which is 13.5 fM, compared to the
K/.3RP for the native peptide

4.3 Titration of copper(I) into theromin

73
97

102
105
108

4.4 Azide titrations into copper(I) theromin to determine strength of
copper(I) binding

1 10

5.1 A model put together by Dr. David Huffman, Dr. Ivano Bertini, and Dr.
Simone Ciofi depicting a possible electrostatic interaction between the
positively charged HAHl and the negatively charged WLN4

119

5.2 SDS PAGE showing a highly pure cleaved WLN4

121

5.3 SDS PAGE showing pure HAHl protein

122

5.4 1H-15N HSQC of apoWLN4 (red) overlaid with Cu(I)WLN4 (blue)

126

5.5 A 1H-15N HSQC overlay of 15N C15A HAHl before addition of
CuWLN4 (red) and after (blue)

5.6 1H-15N HSQC of 15N C12A HAHl (green) titrated with Cu(I)WLN4
(blue)

5.7 A. C15A Atxl (green) titrated with wtCcc2a (red), B. C18A Atxl
(green) titrated with wtCcc2a (red), C. wt Atxl (green) titrated with

127
128

C13A Ccc2a (red), D. wt Atxl (green) titrated with C15A Ccc2a (red)

134

5.8 UV-Vis titration of copper(I) into apoWLN4 to nearly one equivalent

135

5.9 Titration of CuWLN4 with the mutant C15A HAHl to one equivalent

136

Xl

List of Figures—continued

5.10 66.5µ? Cd(II)WLN4 was titrated with the mutant C15A HAHl

138

5.11 apoWLN4 elution profile from a high resolution gel filtration column

139

5.12 apoC15A HAHl elution profile from a high resolution gel filtration
column

5.13 Cu(I)WLN4 elution profile from a high resolution gel filtration
column

5.14 Cu(I)WLN4/C15A HAHl elution profile from a high resolution gel
filtration column

5.15 XANES data ofthe proposed interaction between 3 eq C15A HAHl

139
140
140

and 1 eq Cu(I)WLN4

143

5.16 k3-weighted EXAFS data

143

5.17 Fourier transforms of the Cu(I)WLN4 (blue) and 3:1 C15A
HAHl :Cu(I)WLN4 interaction (red)

144

5.18 Possible mechanism for copper(I) handoff from HAHl to WLN4

145

5.19 Favored intermediate model based on NMR experiments

146

6. 1

Hg(II) NMR spectra at the various pH values, indicating a change in

the coordination environment around the mercury(II)

6.2 Raw data of the PAC experiments

155
157

6.3 Electronic difference spectra of Hg(II) complexes of HAHl with
changes inpH

6.4 Hg(II)HAHl high resolution gel filtration curves showing the elution

161

profiles from a superdex 75 10/30HR column (pH range 7.5-10.2)

163

6.5 apoHAHl high resolution gel filtration curves showing the elution
profiles from a superdex 75 10/30HR column (pH range 7.5-10.2)

163

xii

LIST ABBREVIATIONS

Ag(I)

Silver©

Arg or R

Arginine

Asp or N

Asparagine

ATP7A

Menkes Gene

ATP7B

Wilson Disease Protein Gene

Atxl
BASIL
Ccc2

Yeast Homolog to HAHl
Bauer's Axially Symmetric Independent Ligands Model
Yeast Homolog ATPase to Wilson Disease Protein

Ccc2a

First Metal-Binding Domain of Ccc2

Cd(II)

Cadmium(II)

CSV

Chemical Shift Variation

Cu(I) or (II)

Copper(I) or (II)

CueR

Copper Efflux Repressor Protein

CysorC

Cysteine

DTT

Dithioltheitol

ESI

Enzyme/Substrate/Inhibitor Complex

ESI

Electrospray Ionization

ES

Enzyme/Substrate Complex

EI

Enzyme/Inhibitor Complex

Eq

Equivalents

EXAFS

Extended X-ray Absorption Fine Structure
xiii

List of Abbreviations—continued

GIy or G

Glycine

GSH

Glutathione

GST

Glutathione S-Transferase

HAHl

Human Copper(I) Metallochaperone

Hg(II)

Mercury(II)

His or H

Histidine

HR

High Resolution

HRGF

High Resolutin Gel Filtration

HSQC

Heterospin Quantum Coherence

IPTG

Isopropylß-D-1-Thiogalactopyranoside

LB

Luria-Bertani

Lys or L
MerR

Lysine
Mercury Repressor Protein for mer operon

nm

Nanometers

NMR

Nuclear Magnetic Resonance

NOE

Nuclear Overhauser Effect

NQI

Nuclear Quadripole Interaction

PAC

Perturbed Angular Correlation

SDS-PAGE

Sodium Dodecyl Sulfate Polyacrylamide Gel Electrophoresis

Ser or S

Serine

SOC

Super Optimal Culture

TCEP

Tris(2-carboxyethyl)phosphine
xiv

List of Abbreviations—continued

TRI

Synthetic Triple Helix Peptides

Trx

Thioredoxin

TyrorY

Tyrosine

UV-Vis

Ultraviolet Visible

WLN#

Wilson Metal-Binding Domain #

WLNP

Wilson Disease Protein

XANES

X-ray Absorption Near Edge Structure

xv

CHAPTER 1

BLOOD CLOTTING MECHANISMS AND INHIBITION
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Figure 1.1: Illustration of the blood clotting cascade (1-4).
Blood clotting problems are very prevalent in the United States. The

American Heart Association reported that more people die of a thrombosis (blood
clot) than of AIDS and cancer combined. Most of these deaths occur from what is

called a pulmonary embolism (PE) (5, 6). More commonly blood clots exhibit
themselves as deep vein thrombosis (DVT) (5, P). There are several drugs available
1

that can significantly reduce the possibility of getting, or even help dissolving, a clot.
The most commonly prescribed drug on the market today is Coumadin® (warfarin); it
works by inhibiting vitamin K from activating proconvertin (FVII). FVIIa activates
Christmas factor (FIXa) that activates Stuart Factor (FXa) which in turn cleaves

prothrombin (inactive) to produce a-thrombin (active) (13, 14) (Figure 1.1). aThrombin is the penultimate step in the blood clotting cascade, and is essential for
both procoagulation and anticoagulation.

More recently, drugs are being developed that inhibit a-thrombin directly.
Direct a-thrombin inhibition would be a stronger and faster anticoagulant. One such
drug contained hirudin, a small peptide, that directly binds to a-thrombin to inhibit its
ability to cleave fibrinogen. This inhibition is unique in that it binds to a-thrombin

stronger than any other direct inhibitor to date. It also exhibits the ability to bind to

a-thrombin in both its anticoagulant and procoagulant state. Drug discovery is
moving toward small peptides rather than organic based molecules. This may lead to
fewer side effects in the long run, as the peptides can be recycled by the body's
natural proteases, resulting in less metabolites to combat.

1.1 Blood Clotting Cascade

The blood clotting cascade involves a very complicated, yet scrupulously
regulated, set of proteases that work in concert to create and destroy clots to facilitate
repair of blood vessels. Figure 1.1 illustrates the complexity of this process as well
as how tightly controlled it is. The blood clotting process involves two different

pathways, the extrinsic and intrinsic. The distinction between the two pathways is
2

reflected by their names, the extrinsic requires factors not typically found in the
blood, whereas the intrinsic pathway involves only factors inside the blood (15).
1.1.1 Extrinsic Pathway

The extrinsic pathway is the first pathway activated when damage is done to
the cells of the vessel wall (3, 16-18). There has been evidence that it plays a role in
the intrinsic pathway as well (See Section 1.2). It has been shown that tissue factor

(TF) is constitutively expressed in many cell lines, especially those near blood
vessels, i.e. skin surface, brain, lungs, and even the placenta {19, 20). Tissue factor is
a membrane bound glycoprotein that has a high affinity for Factor VII in the blood

(3). A cut in the blood vessel exposes the TF to the Factor VII and forms a complex
with it in the presence of Ca(II) (21). This complex is essential to the initiation of the

extrinsic cascade because it activates FVII, which can then go on to activate FX and
FIX. From this point, the scheme gets highly complicated and much more regulated
to propagate clots. This is also the point where the two clotting mechanisms
converge.

1.1.2 Intrinsic Pathway

In the intrinsic pathway clotting occurs with factors inside the blood (22).
This clotting mechanism is more complicated than the extrinsic and involves a more
sophisticated mechanism. In this cascade FXII is activated to FXIIa when it comes in

contact with a negatively charged surface such as glass or in disease states (22-25).
The function of FXII is still unclear because individuals with deficiencies don't
3

exhibit hemological problems. The intrinsic coagulation cascade can be used as a

measure for clotting times in the blood. This indicates the amount of clotting factor

in the blood, and it is a measure to how "thin" the blood is; thin refers to the fluidity
of blood. FXII was discovered in 1980 when a person with no other hemological
issues exhibited prolonged clotting times (25, 26). A study discovered her blood

didn't contain the clotting Factor XII which is the initiation step of the clotting
cascade by interaction with the glass surface. In vivo, however, the intrinsic pathway
can be activated by articular cartilage (a subset of cartilage between joints),
endotoxin, L-homocysteine, skin, chondroitin sulfate, calcium pyrophosphate and a
clot already in progress (which seems to be an accepted common process for this
coagulation cascade) (22, 27, 28).

The activation of FXII leads to conversion of prekallikrein (also known as

Fletcher factor) to kallikrein, which further activates FXI (22). Ultimately the newly
activated FXIa goes on to activate FIX which then associates with FVIIIa and Ca(II)
to make the tenase complex that activates FXa (29-31). This is essentially where the
two processes converge.

The intrinsic pathway has been described as having two functions, response as

inflammation from disease and as a way to maintain a clot. Clots have the proper
charge on them to elicit the intrinsic response until the wound is repaired and
activated a-thrombin has been brought to physiological levels.

4

1 . 1 .3

Clot Formation

The remaining clotting mechanisms occur regardless of the initiation of the

clotting event. Once FX has been activated the clot formation moves along quite
quickly toward clot formation. FXa is the clotting factor that cleaves prothrombin
(FII) to a-thrombin (FIIa). a-thrombin is the penultimate step in clot formation.
Once active, which will be more clearly defined later in this discussion, it has two
major jobs for creating clots. First it cleaves fibrinogen into fibrin monomers which

is the clotting material itself and second it works in conjunction with Ca(II) and fibrin
to activate FXIII. FXIII plays an essential role as it crosslinks the fibrin molecules to
make the clot hard and impenetrable.

5

1.2 a-Thrombin

a-Thrombin (Figure 1.2) is the next to last step of the blood clotting cascade.
It cleaves fibrinogen into fibrin monomers and activates Fill so the clot can harden
active site

exosite I

5

exosite!

C

A.etectrostatic

».hydrophobic

Cfibrinogen

Figure 1.2: Thrombin surfaces describing the electrostatic and hydrophobic regions,
as well as where fibrinogen fits into the structure. For Further information about the

importance of these features of the exosites, refer to Section 2. l(i Z)ABEII is exosite
II, ABEI is exosite I and the active site is where the catalytic triad is located.

(Figure 1.1). a-Thrombin has been the target for many drugs to date, such as heparin
and Leprudin® (rHirudin). These sorts of drugs act much more effectively than, for
6

instance, warfarin, which works by inhibiting vitamin K dependent synthesis of FII,
VII, IX, X, and regulatory factors: proteins C, S, and Z (32, 33). The drawback with
warfarin is the need for it to slowly build up in the bloodstream. Warfarin is not a

fast acting molecule and it takes time to properly regulate the dosage. Because of
this, it is typically taken in conjunction with heparin for the first two weeks. This is
both expensive and time consuming; whereas direct a-thrombin inhibitors would be

more beneficial. Heparin is a direct a-thrombin inhibitor, but there are problems with
long term use of heparin, i.e. the heparin-a-thrombin complex may induce creation of
antibodies to the extent that it would actually cause other clotting elsewhere. Some
emphasis has been placed on finding a direct a-thrombin inhibitor that would work

more effectively and alleviate the issues associated with heparin. There has been a
plethora of research associated with a-thrombin in its various forms to try and
understand its activity and regulate it. a-Thrombin is a very diverse enzyme that can
carry out a clotting event and also initiate destruction of the clot once it is not needed.

This section will discuss the nuances of a-thrombin that allow it to do its job and how
it is regulated and inhibited.
1.2.1 Proteolytically Cleaved Forms of a-Thrombin

a-Thrombin has four distinct forms, each differing by the cleavage of small
peptide fragments. For example, a-thrombin exists in the blood as prothrombin
(concentration in the blood 1.2µ? (34)), which is then cleaved by FXa to create athrombin (in this discussion it will be noted as "thrombin") (concentration in blood independent of clotting event - 0.06 µ? - 0.09 µ? (34)) which is the most common
7

form. The cleavage of a-thrombin by Factor Xa occurs after an extrinsic event has

occurred (i.e. a laceration of the blood vessel). It is the most specific protease form,
and can perform all the activities of the a-thrombin protease. Once in the active form,
a-thrombin can be further degraded by autolytic cleavage, or by FXa to make two
distinct forms, ß and ?-thrombin (35). These two, less active forms are created by
cleavage of the B-chain of a-thrombin. The ß-thrombin is created by cleaving the Bchain between Arg- 106 and Tyr-107. ?-thrombin is created by further cutting of the
ß-thrombin B-chain between Lys- 190 and GIy- 191.
1.2.1.1 a-Thrombin

a-Thrombin is a serine protease whose main function is cleavage of soluble
fibrinogen into insoluble fibrin molecules.

a-Thrombin is made of two chains

connected by one disulfide bond; the ?-chain is composed of 36 amino acids (36, 37)
and the B-chain contains 264 amino acid residues (38). The structural features of a-

thrombin are 2 exosites (39-42), a sodium binding site (12, 43-45), fibrinogen
recognition site (46-48), an active site containing the catalytic triad, and various other
sequences that recognize other inhibitors and small molecules (Figure 1.2). Each of
these features will be discussed in detail to understand how all these sites work in
concert to allow a-thrombin to function.
1.2.1.1.1 a-Thrombin Exosites

Thrombin has two exosites that are highly positive and recognize certain
binding partners (Figure 1.2 and 1.3). The site labeled as exosite I binds a whole
8

host of different molecules such as: fibrinogen (49-51), fibrin (49, 50, 52), residues
54-65 of hirudin (7, 50, 53, 54), thrombomodulin (55-58), a-thrombin receptor (59),
and an acidic portion of the heparin co-Factor II (60). Exosite 2 binds heparin and
other similar molecules (61-64), the chondroitin sulfate moiety of thrombomodulin
(65, 66), and the inhibitor hemadin (11, 39). Other molecules target both exosites,
such as FV and FVa (40, 41, 67), FVIII (39, 68), and bothrojaracin (69, 70). Nearly
every event involving a-thrombin utilizes the exosites in one way or another.
Huntington (2005) described ratios of negative charge: hydrophobicity was important
in discriminating the use of one exosite from another (11). Table 1.1 shows different
negative charge/hydrophobicity ratios for various exosite targets. Exosite I favors
targets with a negative charge/hydrophobicity ratio of approximately 1, whereas
exosite II favors targets with a negative charge/hydrophobicity ratio nearly 2.5 times
larger.

This suggests that the exosites can accommodate differing levels of

hydrophobicity. An interesting experiment would be to cleave off the negatively
charged residues and determine whether the inhibitors become more promiscuous;
there are no current studies reported in the literature that have looked at this.
Exosite I has some hydrophobic residues on the surface, whereas exosite II

has none (71). This accounts for the negative charge/hydrophobicity ratio described.
Another interesting feature of these exosites is they are exactly opposite each other in
location on a-thrombin and have allosteric control of the nonbinding exosite (i.e.
hirudin binding to exosite I causes an allosteric shift in exosite II to make it

inoperable as well). This is an important control mechanism for a-thrombin, wherein
9

one binding partner controls the activity of the enzyme rather than multiple binding
partners which would disrupt all activity.
1.2.1.1.2 Sodium Binding

Second in importance only to the exosites is the sodium (Na) binding site.

This site regulates what function thrombin is going to perform. For example, when
sodium is bound, a-thrombin is in the coagulant form because it cleaves fibrinogen
with high specificity. When sodium is not bound it becomes an anticoagulant, by
binding to thrombomodulin - increasing its affinity for protein C activation (44). The
nomenclature for these two states is "fast" and "slow", related to the procoagulant
activity.

10

Table 1.1: Relative ratios of anionic character vs. hydrophobic character to describe
the selectivity characteristics between the two (11).
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Sodium binding has an allosteric effect on the a-thrombin molecule; this has
been noted in the crystal structures in the literature of both the fast and slow forms
(Figure 1.3) (43). One way the allosteric control was observed was from the

structures that indicate many changes that took place and even blockage of the active
site in the absence of sodium (71). The sodium plays a major role in regulation of the
enzymes activities. In the blood, the a-thrombin is available in nearly equivalent
concentrations of both sodium bound and unbound (approximately 2:3 Na:Apo). This
is due to the concentration of salt in the blood (14OmM) being insufficient to
completely saturate the enzyme. A corollary to these findings is that a-thrombin
molecules with a dysfunctional Na binding site lead to bleeding issues (43, 71). The
proportions of fast and slow forms of a-thrombin allow for direct control by the
substrates themselves. Since a-thrombin has such a diverse list of duties it needs to

be very tightly regulated to keep the blood fluid yet allow localized repair of vessels.

12

Catalytic Triad

Si í«fO
[?

SzZXvZ

Catalytic Triad

Sodium Binding Site

Figure 1.3: Thrombin makes some extensive allosteric changes upon binding of sodium.

Top, sodium bound, shows the open active site of thrombin, whereas; bottom, apo form,

shows the active site blocked by an allosteric shift to close off the catalytic triad. Fast
form, top PDB ID: 1SG8, and Slow form, bottom, PDB ID: ISGI (12).
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1.2.1.1.3 a-Thrombin Active Site

The active site is where the fibrinogen cleavage occurs. a-Thrombin is a
serine protease, which consists of a catalytic triad used in cleaving fibrinogen into
fibrin monomers. The active site is located in the B chain of the protease. This is
where the catalytic triad resides, His57, Aspl02, and Serl95 are located (61). The
catalytic triad works by aspartate removing the proton of histidine which in turns
weakens the O-H bond of the serine, in essence lowering its pKa to allow it to attack
the carbonyl carbon of the peptide and proteolytically cleaving the amide bond (72,
73). The specificity for fibrinogen stems from its attraction and orientation on exosite
I.

1.2.1.1.4 a-Thrombin Functionality

a-Thrombin is the penultimate step in the blood clotting cascade, and it also
has the reverse activity of anticoagulation by activating protein C. Some of athrombin's activity as a procoagulant enzyme has been discussed in Section 1,
however, the anticoagulation features need some discussion here. a-Thrombin's
anticoagulant abilities are somewhat indirect in that thrombomodulin binds to

thrombin (slow form), which allows for activation of protein C (an anticoagulant
protein). Protein C, in conjunction with protein S, then cleaves and inactivates FVa
and FVIIIa preventing prothrombin cleavage and ultimately stopping creation of
active protease (74, 75). Thrombomodulin is a membrane protein expressed on the

surface of endothelial cells (76, 77). The thrombomodulin-a-thrombin complex
14

increases the activation of protein C a thousand-fold, and prevents any fibrinogen
lysis by competing for its binding site (75, 77). Once protein C is activated, it
complexes with protein S, which exists in the blood either on platelets or endothelium
(78-81). This complex, as stated before inactivates FVa and FVIIIa (Figure 1.4).

Blood FkMf

Figure 1.4: A cartoon describing the anticoagulant abilities of a-thrombin as it binds
to thrombomodulin, and activates protein C (75).
Blood coagulation in the body requires a lot of maintenance and tight
regulation in order to keep our blood in a fluid state during normal function and then
quickly make a clot where necessary to prevent blood loss and sepsis. The
15

coagulation cascade is ultimately set up to highly favor the anticoagulant
mechanisms. However, when there is intrusion to the system, whether that be a cut or

infection, only a very small amount of initiator is needed due to the very large
turnover rate for these proteases, hence the cascade. It is very much like a waterfall,
it starts off slow then all of a sudden, and it picks up speed very quickly to protect the
circulatory system.
1.3

a-Thrombin Inhibitors

The coagulation cascade does its job with accuracy and speed, but there are

times when there is a breakdown in the system. In these cases therapies are needed to
regulate the system until physiological conditions return. Overclotting of the blood
can occur for many different reasons, from too much clotting factor present in the
blood, to problems with protein C or protein S (previously discussed as anticoagulant
proteins), or trauma (i.e. either intrusion such as a blow to a vessel or surgery).
Typically clotting in the legs would not be an issue, however, the blood clots
sometimes aren't completely hardened like a normal clot and can break off and travel

closer to the lungs, which ultimately prevents oxygen from being taken into the blood
(when a clot is in the lungs it is called a pulmonary embolism). Even though there are
many different ways to end up with overactive clotting, the therapies are the same.
Most often when a clot is noticed there are two therapies that are administered
simultaneously, warfarin and heparin. Heparin binds directly to a-thrombin and
inhibits it very effectively, while warfarin blocks vitamin K dependent synthesis of
FII, VII, IX, X, and regulatory factors: proteins C, S, and Z (32, 33). The issue with
16

warfarin, is that it is a dose response inhibitor, and therefore needs to build up in the
system and be constantly monitored for proper "thinness" of the blood.

While these therapies are very useful and effective, they aren't without
problems. Warfarin, has been approved for use since the 1950s and was originally
(and still is today) used as a potent killer of rodents (by causing deadly bleeding
events), however the issues with this drug are its interactions with a lot of commonly
used medicines (i.e. aspirin and other NSAIDs - Non-Steroid Anti-Inflammatory
Drugs) and interactions with foods. Heparin, however, is used quite often as a quick
and direct inhibitor of a-thrombin, but it too has its problems, such as heparininduced thrombocytopenia. Thrombocytopenia is the development of low platelet
count due to heparin-dependent IgG antibodies that are formed and activate the

platelets (82). Briefly the mechanism involves IgG induction toward the heparin
bound to platelet Factor 4. The tail of the IgG then binds to a protein receptor on the
platelets that activates them to create microparticles. These microparticles induce the
formation of clots, and diminish the level ofplatelets in the blood (82-85).
These drugs and issues are only the most common among a whole host of
issues that are related to different anticoagulation therapies. For this reason, there has

been a lot of interest in direct a-thrombin inhibitors that could effectively inhibit its
activity. One such molecule is the leech inhibitor hirudin, having the trade name
Leprudin (which is a recombinant form of hirudin).

17

W

E17

Figure 1.5: Charged Surface map of rHirudin (desulfonated tyrosine 63). This is a
stereo view each being 180° from each other (70).

1.4

Hirudin

Hirudin (Figure 1.5) is a small, 65 amino acid residue, peptide inhibitor from
the leech Hirudo medicinalis (7, 54, 86). Its structure has a hydrophobic core made
of the N-terminal portion of the peptide containing three disulfide bonds holding it
rigid and a very hydrophilic (acidic) C-terminal end (87). There is a posttranslational
modification of a sulfated tyrosine at residue 63, which is not present in the
recombinant form (87, 88). This difference between the two structures accounts for a
10 fold decrease in activity for the recombinant form. It has been found to bind to a-

thrombin very strongly (K,=21 fM (89) for recombinant, some previously have
reported K1=IOO fM (54)), with high specificity. The difference in the inhibition
constants is due to the differences in the amino acid sequences.

18

There are a few NMR structures that have been developed of the hirudin
structure itself (88, 90). The main goal of these structures was to understand whether
the modified tyrosine could be the reason for the difference in inhibition constant. To

date, it is still unclear exactly what role if any the sulfonated tyrosine is playing, even
though there has been speculation it helps in exosite I binding. Many groups have
tried different expression systems to see if the inhibition is affected and what the

L65

K224

D222
G193

D 2 21

E192

Figure 1.6: Hirudin, the blue sticks, is shown bound to thrombin. The red spacefilled residues are implicated in the fast form of thrombin, and the green are

implicated in the slow form. The yellow space-filled residue is lys-244 which plays
an important role in hirudin binding. It is important to note that hirudin binding is
independent of sodium binding (7, 8).
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phenotypes of the protein were (Table 1.2).

As previously stated hirudin binds to exosite I, which is the same place
fibrinogen binds. This feature makes this peptide a very advantageous therapy for
patients that are prone to some of the adverse side effects of the other medications.

Many crystal structures exist of hirudin, and many homologues, binding to athrombin at exosite I (54). Figure 1.6 shows hirudin bound to a-thrombin, and
interestingly not only does it bind to the exosite , but also to the active site as well.

These finding are novel because only recently has the hirudin/a-thrombin structure
been deconvoluted. The technology wasn't available to get a clear idea where and
how hirudin binding was occurring.

Earlier studies used a combination of

crystallography and structures of hirudin binding to determine with low resolution the
structure of hirudin bound to a-thrombin.

Hirudin binding to a-thrombin has a big impact on the blood environment
because not only does it prevent fibrinogen binding and ultimately cleaving, it also
prevents Factor V, VIII, XIII from binding as well (87, 91). One exciting feature of
hirudin binding is that it can bind and inhibit fibrin bound a-thrombin. This is a

major benefit as the fibrin-a-thrombin structure has a large impact on the increase in
thrombus size.
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Table 1.2: A list of different expression systems tried as hosts for over expression of

rHirudin (87).
?
o
C
CJ

"2

On

os

On

?
Os

Os
Os

C
ce

Ou

ce

o

(u

c

Z 2

j=^
Cf--

?

o «

^o

•r

o

¦£ B

155 e
"°
? '?
S

C
?

e

V Dj

?7

«I

Ii
C

?

I»
ce

3
ce

>->

— -s
O

C

o .2

O
CJ

.2 -S

2 -tí cu 2

•i*

-c -C

C

_cj
'3

C

-i P ¦§:<=
.fcs "3

ce
e
s—

?

?-

cu

S3

?.
X

c .a
^

ce

? ?

IS
* °X
?

CJ

's Ja
e

¦o ce

S
ex, >
?

CJ
Sn

CJ

J=

SP
CJ

£

O
J=

C
O

?3

ce

o 2

¦2

?

1/5
CJ
?-

CJ

-a
c
S3

Q C
·« —

?

Cu

oí B * ·=

ce

-O oí

?

c

.0
'w

.ce -s e —,
i—i
c ,ce
O -a H
S»
-a
tö
S ~B ? .su e«?
o
C

o .2

eo

?

J=
¦f->

'? 'ce

-o
U

.S c

e u
Sh U

.£

¦Sí
2
¦o

?
«
ce

Z .S

co

— (N

,ce

> >
X X

S3

/-^ TD
CJ CJ
CJ

?. s

"?

?

ce

o

2

·*-·

-2
J3

?
v>

C

?

o
Sh

U
U-

IZl C/3

e ¿

S
V °
? °
?

i?

i

(N

C/3

t/3

hJ

e ~??~??

Ü0

? e e

? «? "I

— o

Dh

CJ
U-

r/5 5j
O cj
CJ
ir¿

taOO hJ

^bo O
m

'33
¦*-»

CJ -SS
U
-?

S^ ce bu
C ÖO -D
- e ß e
o
¡~

"?

CJ
sU
CJ

OD

e

e

it
?

Tf — -H

H-f

hJ

O

s-3

CD

C

_?
"^ **
2 »
Cu "S

H, Q S

-d

O

ce -Sa

d cu
ce

S -hs
Q
-*-» «s;

Ci.

&o
Co

çs

g o s»1

k~ ^v3

•sC §S)

¦a Su Q

s -s
u:

g>l g,

3 U^

o _-»

(J- ^ CJ

21

CJ
?

o

ce

e

CJ
O

X

CQ

The hirudin homolog Lepirudin® was approved in 1998 by the FDA as a
therapy to combat heparin-induced thrombocytopenia (105). Lepirudin® is made
recombinantly by yeast and is the recombinant form of hirudin with several

modifications: tyrosine 63 is not sulfonated and an isoleucine replaced a leucine at the
N-terminus.

Since the success of hirudin, there have been other direct a-thrombin

inhibitors discovered. One in particular that shows much promise is theromin. It is a
small 67 amino acid peptide capable of binding very tightly to a-thrombin, and
completely shutting it down.
1.5

Theromin

Theromin is a 67 residue peptide capable of wrapping itself around a-

thrombin as it inhibits (89). This peptide contains 16 cysteines capable of making 8
disulfide bonds which seem to be essential to elicit a strong inhibition a-thrombin
inhibition. These observations were from mass spec studies in conjunction with
inhibition studies that found the monomer had a much decreased inhibition constant

than did the dimer form (dimer Ki=I 2 fM, while monomer was much lower) (89).
Theromin' s inhibition constant makes it the strongest inhibitor to date. To date there

is little known about this peptide and therefore is the crux of this study. It is very
important to understand whether there is a difference in inhibition properties between
native and recombinant hirudin (which preliminary results indicate not, based on
comparison of Salzet' s (89) wildtype theromin studies and this project's recombinant
studies). It would also be important to more fully understand how the structure
22

behaves and get structural data for binding to a-thrombin. A combination of this data
and possibly even analogs would lead to an even stronger direct a-thrombin inhibitor.
1.6

Physiological Significance of Theromin

Little biophysical data has been collected for theromin. However, it is
important to understand the physiological impact of theromin in the host blood. For
example how fast does it degrade in the blood, and further does it maintain the blood

in a fluid state much longer than necessary for the leech to eat? These "big picture"
ideas haven't been explored for this inhibitor nor has it been for a similar inhibitor,

hirudin. One could expect these inhibitors are very specific to their targets, so no
alternative binding would occur. Many studies still need to be done on these types of
inhibitors as to what the concentration of the inhibitor is in the saliva of the leech and

whether the leech can use the inhibitor in other ways to regulate its own homeostatic
mechanisms.

1.7

Objectives of This Study

Theromin, as alluded to previously, seems to be a promising new small
molecule for anticoagulation therapy. Wildtype theromin has a K/ of 12 fM, making
it the strongest inhibitor to date. Currently though, the yield from a leech is

insufficient to economically mass produce it, so recombinant technology would be the
alternative. The objective of this study was to express the protein at high levels using
a pET system, and then use the protein made to determine the K, of the recombinant

form. Posttranslational modifications of the peptide in the leech have not been
23

observed, so the K, should be similar to that measured by Salzet (89). A second
objective of this project is to use theromin's homology to metallothioneins and
determine if it too can bind Cu(I). This could serve useful, as therapies are needed
that control copper regulation in people who have Wilson's disease, but many
modifications would be needed to convert theromin from an inhibitor to a chelator, as
it can't serve both functions simultaneously. A combination of these data would
move theromin closer to becoming a new, stronger direct a-thrombin inhibitor.
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CHAPTER 2

COPPER TRAFFICKING PATHWAYS

Copper is scrupulously regulated in cells (7, 2). It is used for many different
processes such as redox activités (i.e. superoxide dismutase) (3) and respiration (i.e.
cytochrome c oxidase) (5, 6), and iron transport (i.e. Fet3) (7). However disruptions
in copper homeostasis can lead to problems such as Wilson's or Menkes disease,
where copper is not regulated properly in the cells (P).

2Cu(I) -? Cu(II) + Cu(O)

O2 * + Cu(II) -? O2 + Cu(I)
Cu(I) + H2O2 -» Cu(II) + OH + OH*
Overall Fenton Reaction: O2-* + H2O2 -» O2 + OH"
+ OH*
Figure 2.1: Chemical equations illustrating how copper(I) can disproportionate into
the highly oxidative copper(II) and further undergo the Fenton reaction to make a
highly reactive hydroxide radical.
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2.1

Importance of Copper in Cells
Copper is moved through the cells in a very precise, well defined manner, and

is important for many processes. It is also very toxic to cells in its unbound form, as it
can create reactive oxygen species (ROS), as well as hydroxyl radicals (10). ROS can
cause damage to a lot of different components of the cell, such as DNA, lipids, and
proteins (11). Copper creates ROS by disproportionating in the cells to form
copper(II) and copper(O), which the copper(I) can then undergo the Fenton reaction to
create what is called a hyperactive hydroxide radical (12) (Figure 2.1).
This is very harmful to the cells and has been shown to lead to cancer (13, 14). The
reason this is harmful is because copper(I) can disproportionate in water to become
copper(O) and copper(II). One such defense is the use of superoxide dismutase; this
enzyme catalyzes dismutation of superoxide radicals^'") to molecular oxygen and
peroxide (15). Another way the cells protect themselves from copper-induced ROS is
by making sure there is little to no free copper. In the cells most all of the copper is
either bound in proteins, bound by the glutathione within the cytosol (16), and
possibly a copper chelator found in the mitochondria (17, 18).
2.2

Copper Movement Through Cells
While there is a fine line between copper being a benefit or a detriment, the

cells have worked out very intricate mechanisms and storage procedures for making
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sure the cells can use the copper yet not be destroyed by it (Figure 2.2).
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Figure 2.2: Illustration describing the different fates for copper (1, 18-21).
Copper is first reduced from copper(II) to copper(I) by a metalloreductase outside the
cell either as the metal is transferred into the cell or just before by proteins encoded
by Frei-7 genes (22-24). The copper is moved into the cell by a high affinity
permease-like protein, Ctrl (25). Ctrl utilizes its methionine rich structure to move

the copper through it into the cytosol (25, 26). Once in the cytosol, copper is picked
up by several different molecues: CCS (27, 28), HAHl (29-31), metallothioneins
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(19), glutathione (32), and likely a few undiscovered transport proteins. CCS is a
direct target for Cu/Zn superoxide dismutase, most often under copper limiting
conditions (27). The HAHl binds copper and delivers it to either Wilson disease

protein (33) or Menkes protein (34). These two latter proteins are used by cells to
either remove excess copper or move more copper into the cells respectively. There
are some low molecular weight molecules found in the cytoplasm that bind up copper
for storage and/or delivery to other proteins; for example the copper ligand found in
the mitochondria is found in the apo state in the cytosol binding up copper to take
back to the mitochondria for storage (1, 35). Finally, glutathione is found in cells at
up to 5mM, and has an affinity for copper(I) in the millimolar range (32). This is
very important, as described previously, because copper is toxic to the cells due to
disproportionation and subsequent superoxide formation. Inside the cells, there is no
free copper in solution (36).

There is one other compartment where copper is found, the mitochondria (1,
35). It has recently been shown that the mitochondria have its own pool of copper
that it uses to create the various cofactors involved in cytochrome c oxidase assembly.
The copper pool isn't just free copper, it is a pool of ligated copper by a small
molecular weight molecule, similar to that of methanobactin (1, 35). It is believed
this ligand could possibly act as the siderophores do for iron by leaving the
mitochondria to find copper and bring it back.
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2.2.1

Ctrl Proteins
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Figure 2.3: Predicted 2D representations of different types of proteins that move
things across membranes. The Ctr protein family is a mix of a transporter and a
channel.

Human Ctrl is an integral transmembrane protein containing a trimer of 23
kDa monomers each containing three alpha helices (37-39). Data predicts this
oligomerization is necessary for transport of copper into the cells, and that the
interface between the tri-helices is important for copper transport (37). Ctrl is very
interesting in that it doesn't behave like a typical transporter or a channel. Unger et.
al. (2006) showed structurally that this protein is novel in its structure, making it
difficult to put it in a proper class of transporters. This work was done by cryelectron crystallography on 2D crystals in native phospholipid bilayers (Figure 2.3)
(37).
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Figure 2.4: A.) A dimer of trimers showing the Ctrl as it spans the membrane. B.) A
slice through the structure in A. C.) and D.) is a longitudinal slice of the extracellular and
intracellular portion respectively(S).
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Figure 2.5: A and B show helix alignment of the helices that compose Ctrl . C-D is
looking down the 3-fold axis from the extracellular, middle and intracellular portions,

the pore forms a cone shape (8).

Unger described, as Figure 2.3 depicts, that Ctr is a combination transporter
and channel. Another interesting feature of this protein is that its transport is
"passive", in that it doesn't require ATP to provide energy for the process. This
could account for previous observations that transport is a slow process for this
protein and there is a low turnover rate. More recently Unger et. al. determined a
projected 3-dimensional structure of this protein (Figure 2.4 and 2.5). As determined
previously, there are several residues residing in the second transmembrane domain

that are important for copper transport. Structurally, however, there are three main
40

features of this protein: I. the extracellular N-terminal domain containing two regions
rich in histidines and two met motifs containing many methionines arranged as either
MXM or MXXM (40, 41), where the M2 region (MMMMPM) is imperative for
copper uptake in limiting conditions (26, 41-43), II. Three monomeric triple helical
structures (TMl -TM3) forming a "pore" in the lipid bilayer for transport and III. The
C-terminal tail containing cysteines that have been shown, at least in yeast, to bind
copper and be able to directly hand it to both Atxl (copper chaperone) and Ccc2
(copper ATPase) (4) (Figure 2.6).
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Figure 2.6: Cartoon representation of the Ctrl (4).

The interactions of the C-terminus is very important to understand what the
fate of copper is when it comes into the cells (4). As previously mentioned, copper
can be transferred in vitro from the C-terminus to the Atxl (44). This is a crucial
relationship because there is no copper free in solution, so copper has to be
transferred from one protein to another with an affinity gradient sufficient to keep it
moving toward its target (32). It has been shown however the glutathione in the cell
has a millimolar affinity for copper, but compared to chaperones like HAHl, having
an affinity in the femtomolar range, it is not a competitor; however other reductants
such as dithiothreitol (DTT) and tris(2-carboxyethyl)phosphine (TCEP) have very
high affinities for copper(I) and must be removed from solution prior to experiments
42

(45). Glutathione may protect the copper by providing a third ligand to help protect
the copper until it reaches its target (16). Data has shown that glutathione is able to
transfer copper to many metalloproteins such as the copper metallothioneins (16, 46,
47). Data also has shown that glutathione can act as a ligand to Cu(I)HAHl which in
turn helps maintain it in a 2-coordinate state (48). HAHl is the next step in the
journey the copper takes to reach its final destination. HAHl is one of a few
metallochaperones that shuttle copper around the cells.

2.2.2 Copper Chaperone for Wilson Disease Protein (HAHl)
Once inside the cells, the targets for copper aren't sufficiently close spatially
to the Ctrl to directly receive the copper. For this reason chaperones are needed to
move the copper to its final destination. Many of the copper chaperones have been
shown to move more many different metals, and their structures have been elucidated.

For instance, HAHl has been shown to bind platinum (as cisplatin) (49), mercury(II)
(34, 50), copper(I) (34, 50), silver(I) (50), and cadmium(II) (34, 50). This seems to
be a crucial role for these chaperones to have as a few of these metals have
detrimental effects on the cells.
2.2.2.1 Human Atoxl: HAHl

HAHl is a 68 amino acid protein that is responsible for delivering copper(I) to
the domains of both the Wilson disease protein and the Menkes protein (33, 34). It
has subfemtomolar affinity for copper(I) (45, 51). The very close similarity of these
values indicates the handing off of copper is kinetically controlled rather than
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thermodynamically controlled. HAHl was discovered by screening cDNA libraries
for a human homolog to the yeast Atxl protein (30). What was discovered was a
protein with approximately 47% homology. The structure of HAHl contains a
ferridoxin-like fold and a conserved metal binding motif, MXCXXC (29). Data also
suggested this MXCXXC motif was used for binding copper(I) in cells. Interestingly
it was also discovered that mutations in the metal-binding cysteines had a dramatic
effect on Fet3 copper(I) incorporation. The C12G mutations had a dramatic effect on
the amount of copper that could be incorporated into the Fet3, whereas the C15G
mutations had little effect (29).

Earlier work using a yeast two hybrid study showed Atxl, the yeast homolog
to HAHl, can deliver copper(I) to Ccc2p, the yeast homolog to both the Wilson
disease protein and the Menkes protein (33, 52). Since these two proteins have a lot
of homology to the respective human proteins, it serves to expect they interact in
much the same way. There have been several studies that indicate HAHl interacts

with the domains of the two ATPases in a copper-dependent manner via the
MXCXXC motif (33, 53-56).
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To date there many structures, both by X-ray crystallography and NMR of
various forms of HAHl. Hg(II)HAHl, Cd(II)HAHl, and Cu(I)HAHl structures have

Figure 2.7: Model of CuHAHl depicting the copper bound to the two cysteines of
HAHl (57).

all been solved by x-ray crystallography (34). However, Cu(I)HAHl and apoHAHl
structures have been solved by NMR (57). In this dissertation the structures of the

apo and copper-bound (Figure 2.7) solution structures and the mercury(H)-bound
structures (Figure 2.8) are most important.

The solution structures of Cu(I)HAHl indicate a copper bound monomer,
which is markedly different from the structure determined by X-ray crystallography
in that the Cu(I)HAHl forms a copper-bridged dimer (57). This could just be due to
a difference in technique for measuring the proteins. It was also noted that even when
copper was bound the ferridoxin-like (ßaßßaß) fold wasn't changed and there were
very small rearrangements in the structure (57).
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Previous work indicated that MerP, a mercury binding protein, contained the
same metal binding motif as HAHl does, and binds mercury(H) a 2-coordinate nature

Figure 2.8:

Model of the Hg(II)HAHl homodimer determined by X-ray

crystallography (34).

(58). So it would be a natural assumption it could bind to HAHl . Data indicates that
Hg(II)HAHl is found in a dimerized state with a supposed distorted 4-coordinate

Hg(II)-S species. The fourth coordinate was noted to be a longer distance than is
required for a covalent bond to the metal (34).
2.2.3 Wilson Disease Protein and Interactions with Cu(I)HAHl
Wilson's disease is an autosomal recessive disorder that affects 1 in 30,000

people. The disease leads to accumulation of copper in the kidney, liver, brain and
eyes (59). Due to the detriment to the body when copper is in excess, many
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researchers have set out to understand how this protein functions so that more
targeted therapies can be discovered.
2.2.3.1 Wilson Disease Protein (WLNP)

Wilson disease protein is a 1465 residue P]B-type ATPase that utilizes ATP to
move copper out of the cytoplasm of the cells (60). Wilson disease protein has a
unique N-terminal tail made of six repeating units that can bind up to six equivalents
of copper(I) (56). This tail can bind a host of different heavy metals, Hg(II), Zn(II),
Cu(I), Cd(II), Fe(III), and Au(III) with different affinities (55, 61-63). The affinities

were determined by using a radio labeled zinc (65Zn) to do competition assays. The
values of the affinities weren't described in this work, except for the fact that the
trend in affinities was Cu(I)»Cu(II)»Zn(II)»Ni(II)»Co(II) and did not have any
binding to either Fe(II) or Fe(III) (55).

There are four main domains on this protein: the 6 metal binding domains
with the ability to accept one copper(I) each, 8 transmembrane helices that creates the
pore for copper transport across the membrane, an actuator domain, and an

ATP/phosphorylation domain containing a nucleotide binding domain and a
phosphatase domain (64).

During copper homeostasis, the Wilson disease protein is localized in the
trans-Golgi network where it can deliver copper to pertinent copper containing
proteins such as ceruloplasmin. Then as the concentration of copper is increased to
potentially toxic levels, it reversibly relocalizes to the plasma membrane or a storage
vescicle (65-67).
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Wilson disease protein's unique feature, as previously noted, is its
approximately 650 residue N-terminal domain. This domain contains 6 homologous
monomers that contain the metal-binding motif GMT(H)CXXC, the histidine residue
replaces the threonine residue in domain 3, and each monomer can bind one

equivalent of copper(I) (57, 55, 56, 63, 68, 69) . To date, constructs of WLN3-4 (70),
WLN5-6 (71), WLN4 (71, 72), WLN2 (73), WLN1-6 (74) and most recently WLN46 (75) have been investigated. Of the constructs currently only the WLN3-4 and
WLN5-6 have NMR structures.

WLN3-4 was unique in that the domain 3 and domain 4 acted independently
of each other (70, 71), which was in contrast to the WLN5-6 that acts as a unit (71).
Data also suggested that WLN3-4 aggregated in a concentration dependent manner,
noted by a decrease in tumbling times with a decrease in WLN3-4 concentration. An

interesting feature of the aggregation issue was that there were no detectable changes
in NOEs with changes in concentration, so the authors suggested it was just due to
random interactions with different patches on the construct. When copper(I) was
added the aggregation was still present, illustrated by higher tumbling correlation
times than would be expected for a single construct in solution (57). Consistent with
the previous note that the domains act independently was the observation that copper
loading prevented WLN4 from interacting with another WLN4 molecule, but didn't
have any effect on the aggregation characteristics of WLN3.
Metal binding studies were also completed on the WLN3-4 construct. The

data suggested that when copper was titrated in at substochiometric concentrations,
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there were detectable changes in the 1H-15N HSQC for both domains. This was
consistent with similar binding affinities for copper, which were determined to be:

(6.3±3.2)xl010 for WLN3 and (2.5±1.3)xl010 for WLN4 (69, 70). The affinities were
measured based on the bicinchoninic acid (BCA) assay. This assay takes into account

the appearance of a distinctive red color that appears upon binding of copper(I) to it.
Once measured, a program is used to determine the affinity constants. Table 2.1
contains the measured affinities for copper by each of the WLNP domains and

HAHl. Chemical shifts in the HSQC were also noted only for the metal binding
region, indicating no changes in the folding of the domains upon metal binding.
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Table 2.1: Tabulated values for copper affinities for the different metal-binding
domains of Wilson disease protein and its copper chaperone, HAHl (69).
Peptide:

Affinity constant, Kcu, M"

WLNl

2.6±1.5xl0

WLN2

3.5±0.9 ? 10

WLN3

6.3±3.2xl0

TtT

WLN4

2.5±1.3xl0

??G

WLN5

2.2±1.0xl0

TO"

WLN6

5.8±2.5xl0

w

HAHl

3.5±1.0xl0

TO"

TO"

W

Finally interaction with Cu(I)HAHl was investigated. NMR data showed
chemical shifts in the metal binding region in both the domains even at
substochiometric Cu(I)HAHl. Again this suggests Cu(I)HAHl has similar affinities
for both domains. However, one unique characteristic was the fact that in WLN4

there were peaks in the HSQC that appeared while others disappeared as Cu(I)HAHl
concentration was increased. This was in contrast to what happened to the WLN3
construct where no peaks seemed to disappear, but rather, a new peak appeared and
increased with increasing Cu(I)HAHl concentrations, this suggests there is slow
exchange phenomenon in the case of WLN3, suggesting there is no complex
formation. WLN4, however, could make a complex with Cu(I)HAHl that increased
as more Cu(I)HAHl was added (a fast exchange phenomenon was observed), but
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WLN3 seemed to accept the Cu(I) from HAHl, rather than form an NMR detectable

complex, consistent with a new set of peaks that just increased in intensity. These
data further strengthen the idea that WLN3 is unique and independent, at least
compared to WLN4. The character of these domains is quite different from the
WLN5-6 construct that acts as a tandem unit. This may be expected because they are

spatially close together with somewhat of a longer linker region separating them from
the WLN 1-4.

WLN5-6 has been shown to exhibit the same ferridoxin folds as the WLN3-4

construct has, and was determined to be a rigid unit that tumbles together (77). With
the rigidity of this structure comes the feature that there can be no metal transfer

between WLN5 and WLN6. The tumbling correlation time for the WLN5-6 was
measured to be 9.1±0.6 ns, which was consistent with twice the tumbling correlation

time for a single WLN6 in solution, as well as what would be expected for a protein
of approximately 16 kDa in size.

Further studies investigated the interaction of the WLN5-6 with both copper
and with Cu(I)HAHl. WLN5-6 can bind two equivalents of copper, and consistent

with the WLN3-4 construct, the folding of the domains were unaltered, described by
chemical shifts in the HSQC spectrum localized to the metal binding regions.
However, interestingly, when Cu(I)HAHl was titrated in, there was no copper

transfer to WLN5-6, indicated by lack of chemical shifts in the HSQC spectrum.
Previous work by Larin et. al. using a yeast two hybrid technique showed that HAHl
interacted with many various combinations of domains, but not with WLN5 or WLN6
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(53).

So this work was further supported biophysically through the NMR

experiments.
In light of this lack of interaction between Cu(I)HAHl and WLN5-6,

Cu(I)WLN4 was titrated into the WLN5-6. The data showed -10% of the copper was
transferred to WLN6 and almost nothing to WLN5.

As the concentration of

Cu(I)WLN4 was increased, more of the WLN6 was coordinated, and some of the

WLN5. The data suggested copper(I) transfer, but did not indicate any detectable
complex formation. These data suggest there are multiple roles of these domains, for

example previous work has shown WLN2 and WLN4 are the primary targets for
Cu(I)HAHl (53, 54, 73), whereas this and other work suggest WLN5 and WLN6

must acquire copper from the other domains (53, 71). These data support the need for
six metal binding domains, as it is a way to regulate and possibly detect the copper
conditions in the cell.

There has also been work on a couple of the single domains, WLN2 and
WLN4. These two domains seem to be the primary targets for Cu(I)HAHl (53, 54,

71, 76). Previous work on WLN2 indicated it was the primary target for Cu(I)HAHl
and could possibly transfer copper to other domains. These observations are not
congruent the work published to date. This indicates, at least in the whole WLN 1-6
construct, all the domains can receive copper directly from Cu(I)HAHl (73). Walker

et. al. indicated that when the cysteines of the WLN2 was mutated, that destroyed the
binding of copper to the rest of the protein. This observation is in stark contrast to the

rest of the data for the WLNP. They suggested it was because of the folding of the
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protein in solution which blocks access of Cu(I)HAHl to the other domains. This

also seems to contradict the latest data for Cu(I)HAHl interaction with WLNP by
NMR studies (74). Bertini's group showed that Cu(I)HAHl could indeed interact

with all of the 6 domains, which makes the story even more complicated because that
is inconsistent with the WLN5-6 data.

This raises the question as to how

physiologically relavent is work on single or multiple domains that don't contain the
whole construct. Achila et. al. showed that there is an interaction between WLN2

and Cu(I)HAHl which supports previous data, as there were chemical shifts that

increased as the Cu(I)HAHl concentration was increased, as well as some broadening
that occurred further indicating complex formation. It seems to be the consensus

WLN2 is a target of Cu(I)HAHl, but what happens following that interaction is still
to be fully elucidated.

Further work has been done on the single domain WLN4. This domain
showed an increase in the amount of complex formation as compared to WLN2. This
was indicated by the difference in tumbling correlation times; 5.5±0.4 ns for HAHl
bound to the WLN2 via copper and 7.2±0.7 ns for the same bound to WLN4. The

higher tumbling correlation time indicates a higher amount of complex formation. A
suggestion for this would be the electrostatic differences between WLN4 and WLN2

compared to and HAHl. WLN4 is highly negative and HAHl is highly positive,
suggesting at least a partial electrostatically strengthened interaction which would
yield a higher amount of complex formation.
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WLN4 seems very interesting in how it interacts with HAHl as it forms a

strong complex. The strength of the complex makes it a good candidate for
elucidating a model for copper hand off. Rodríguez-Granillo et. al. used computer
modeling to try and understand a potential mechanism for delivery of copper (76).
Their data indicated that a 3-coordinate intermediate was energetically more stable
than a 2-coordinate or 4-coordinate intermediate. They suggested also that there are
two 3-coordinate species that exists during the hand off. Current work in this project
investigates the likelihood of this being the case in vitro.
As mentioned previously, the Bertini groups data on the WLNl -6 was

inconsistent with the WLN2 study and the WLN5-6 study. The WLN2 study
indicated that WLN2 interaction was necessary for copper delivery to the different
domains, at least when all six were intact, due to domains being blocked by the
folding of the domains around each other. The WLN5-6 work showed there was no
interaction between Cu(I)HAHl and the WLN5-6; this too is in contrast to what the

Bertini group has discovered. This again leaves the question as to consistency of
construct formations because there is a lot of data that contradicts some of the ideas

that have become dogmas in the Wilson protein field.
The NMR study of the WLNl -6 indicated a complex formation between
Cu(I)HAHl and WLNl, WLN2, and WLN4 (74). The other three domains, however,

only exhibited copper transfer, and no complex formation could be observed. They
also found there was no need for WLNl, WLN2, and WLN4 in order to transfer

copper to the WLN3, WLN5, and WLN6 domains. This is important because some
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previous data had suggested at least WLN2 was necessary for mediating copper
addition to the other domains. In parallel to these findings, they didn't find any
interaction of Cu(I)HAHl with any of the domains where the cysteines were mutated
to alanines, further showing that the interaction of Cu(I)HAHl with the metal binding
domains is metal-mediated, and not electrostatic for example.

Most recently, there was work done on the interaction of WLN4-6 involving
interaction with Cu(I)HAHl (75). This was an NMR study that seemed to show
many things that are quite different from what has been published thus far. The first

was that there was interaction of HAHl with the domains in the absence of copper(I).
This is contradictory to the work by Bertini' s group where they mutated the cysteines
to alanines and did not see any complex formation. This idea will be discussed

further in the results section, as the NMR titrations performed in this project showed
no interactions in the absence of copper. The data further suggested independent
mobility of the 3 domains, which is counterintuitive to the idea that WLN56 acts as a

unit. This data is very contrary to what has already been published and will need to
be investigated further to understand what exactly is going on with these domains.
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CHAPTER 3

MATERIALS AND EXPERIMENTAL METHODS

This chapter will tabulate and describe all the procedures used for the
experiments as well as a listing of all chemicals, reagents, peptides, etc. This list will

include purity and place of purchase. The methods in this section include: protein
expression and purification, as well as theromin kinetics and metal binding studies.
The methods also include NMR, UV-Vis spectroscopy studies to understand the

various coordination environments around the Wilson disease protein and its copper
chaperone, HAHl. A final discussion will involve probing the coordination
environment of Hg(II)HAHl in solution; comparing it to the published crystal
structure.
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3.1

Listing of Chemicals, Reagents, and Peptides

Table 3.1: List of proteins and their respective vectors, tags, and proteases.
Protein:

Vector:

Tag:

Protease:

Theromin

pET42a

Glutathione S-Transferase

Factor Xa

pET32Xa/LIC

Thioredoxin

Factor Xa

HAHl

pETlld

None

NA

C15AWLN4

pET32aXa/LIC

Thioredoxin

Factor Xa

C18AWLN4

pET32aXa/LIC

Thioredoxin

Factor Xa

Cl 5A HAHl

pETlld

None

NA

C12AHAH1

pETlld

None

NA

Wilson Domain 4

(WLN4)

Table 3.2: Reagents, manufacturers, and purities (where available) used in the
following experiments.
Reagent:

Part
Number:

Manufacturer/Distributor:

H Acetonitrile-d3

423106

Sigma-Aldrich

Acrylamide

164855000

Acros Organics

Agarose

15510-019

Invitrogen

L-Alanine

A7627-1G

Sigma Aldrich

Purity:

T5

N-Ammonium

Cambridge Isotopes

Chloride
Ammonium Chloride

A66 1-500

Fisher Scientific

99.8%

Ammonium Persulfate

A3678-25G

Sigma-Aldrich

>98%

L-Arginine

A8094-25G

Sigma-Aldrich

L-Aspartate
Bathocuproine

A9256-100G

Sigma-Aldrich

100868

MP

BP171-25

Fisher Scientific

Difsulfonic Acid

Bis-Acrylamide

64

Table 3.2 Continued
Boric Acid

BP168-1

Fisher Scientific

Carbenicillin

762024

Bio-World

Coomasie Blue R-250

20278

Thermo Scientific

Copper Standard for

SC 194- 100

Fisher Scientific

CNLM-3871-0

Cambridge Isotope
Laboratories

3089

Fluka

D8130-106

Sigma-Aldrich

Dithiothreitol (DTT)

1758-9030

Inalco Spa, Milano Italy

EDTA

BPl 19-500

Fisher Scientific

Glacial Acetic Acid

64-19-7

Fisher Scientific

ICP-AES
13

C515N L-Cysteine
L-Cysteine

Dithionitrobenzene

(DTNB)

13C-D-Glucose

>99%

13C >97%
15N>97%

>99.0%

Cambridge Isotopes

L-Glutamic Acid

G8540-25G

Sigma-Aldrich

L-Glutamic Acid

G1251-100G

Sigma-Aldrich

G425-50G

Sigma-Aldrich

> 99 %

BP178-500

Fisher Scientific

> 99%
>99.5%

L-Glutathione

(reduced)
Guanidine

Hydrochloride(GuCl)
Guanidine

Hydrochloride
Glycine

50933

Sigma-Aldrich

G7 126-1 00G

Sigma-Aldrich

Hirudin

H7386

Sigma-Aldrich

L-Histidine

H8000-5G

Sigma-Aldrich

7647-01-0

Fisher Scientific

Concentrated Nitric
Acid

7697-37-2

Fisher Scientific

Imidazole

56750

Sigma-Aldrich

Indium Standard for
ICP-AES

IAA-049

Ultra Scientific

Concentrated

Hydrochloric Acid
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>99.5%

Table 3.2 Continued
Iodoacetaminde
IPTG

1758-1400

Inalco Spa, Milano Italy

L-Isoleucine

I2752-1G

Sigma-Aldrich

Kanamycin Sulfate

420311

Calibiochem

L-Leucine

L8000-25G

Sigma Aldrich

MEM Vitamins

25-020-CI

Mediatech Inc.
Fisher Scientific

Mercury(II) Choride
L-Methionine

M9625-5G

Sigma-Aldrich

MES

BP300-100

Fisher Scientific

L-Phenylalanine

P5482-25G

Sigma-Aldrich

L-Proline

P5607-25G

Sigma-Aldrich

L-Serine

S4500-1G

Sigma-Aldrich

Sodium Chloride

BP358-10

Acros Organics

Sodium Dithionite

SX0530-1

EM Science

Sodium Dodecyl
(SDS) Sulfate

15525-017

Gibcobrl

S612-3

Fisher Scientific

S393-3

Fisher Scientific

Monobasic,
Monohydrate

BP330-1

Fisher Scientific

S-2238 (Chromogenix)

820342-39

DiaPharma

TEMED

BPl 50- 100

Fisher Bioreagents

>97%

Tetrakis (Acetonitrile)
Copper(I)

346276-5G

Sigma-Aldrich

>99%

T6060

Invitrogen

T8625-1G

Sigma-Aldrich

Sodium Hydroxide
Sodium Phosphate,
Dibasic Anhydrous

>98%

>99.85%

>99.5%

Sodium phosphate,

Hexafluorophosphate
Thiol Sulfide

Quantification Kit
L-Threonine
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Table 3.2 Continued

Novagen

a-Thrombin
Trichloroacetic Acid

BDH0310-500G

VWR

>99.0%

Tricine

807420

MP Biomedicals

Tris

BP 152-5

Fisher Scientific

L-Tryptophan

T0254-1G

Sigma-Aldrich

Tryptone

12111-1

Mo Bio Lab

L-Tyrosine

93829

Fluka

Urea

BP169-500

Fisher Scientific

L-Valine

V0500-1G

Sigma-Aldrich

Yeast Extract

212720

Fisher Scientific

>99%

Table 3.3: List of biological reagents used in the following experiments.
Biological Reagent:

Part Number:

1Kb DNA Ladder
Benzonase

N3232S
23225
70746

Bio-RadReagent
Protein Assay

500-0006

BL21(DE3) Competent Cells
BugBuster® Reagent
Factor Xa (Bovine)
Isoelectric Focusing
Calibration Kit10)Broad pI(pH3-

69450
70584-4
NA

Novagen
Enzyme Research

17-0471-01

Amersham Biosciences

LMW Gel Filtration
Calibration Kit

17-0442-01

Amersham Biosciences

Novablue Competent Cells
QIAprep®
Kit(250)
Spin Miniprep

69825-4
27106

Novagen
QIAGEN

Rainbow Protein Marker

RPN800E
70954-3

GE Lifesciences

BCA™ Protein Assay Kit

Rosetta(DE3) Competent
Cells

67

Manufacturer/Distributor:
NEB
Thermo Scientific

Novagen
Bio-Rad Laboratories, Inc.
Novagen

Novagen

Table 3.4: Listing of instrumentation used for experiments.
Instrument:

Details:

Applications:

GE Lifesciences

Part Number:

Protein Purification (See Table 2.4)

(formerly Amersham)

18-1900-26

AKTA FPLC

OHs Cary 14 UV Vis

Protein Quantification, UV-Vis

Spectrometer

Edinburgh

FL900

Titrations, and Kinetics Experiments
Copper(I) Titrations

Fisher Scientific

Housing AKTA FPLC and Amicon

Model Number:
DU-7400

Protein Quantification

Fluorimeter

Isotemp Laboratory
Refrigerator
UV/VIS Beckman

Diode Array
Spectrophotometer

Sorvall Centrifuge

devices

Pelleting cell cultures,
proteinsand concentrating

Model Number:
RC 5B

Varian 500 MHz

NMR (University of
Michigan, Ann

1H, 13C, and 1H-15N HSQC Experiments

Arbor, MI)
JEOL 400 MHz

NMR (Western

1H, 13C, and 1H-15N HSQC Experiments

Michigan University,
Kalamazoo, MI)
Bruker 600-800 MHz

NMR (Center for
Magnetic Resonance,
Florence, Italy)
Jasco CD

Spectropolarimeter

With

Iu 15-

H- N HSQC, and mobility Experiments

Cryoprobe
Model Number:
J815

Circular Dichroism experiments
Light Scattering
chromatography
and Reverse phase

Shimadzu HPLC

Electrospray
Ionization Mass

Protein mass measurements

Spectometer
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Table 3.4 Continued

Minicycler

Model Number:

Thermocycler
Bioflo310 Fermentor

PTC- 150
New Brunswick

Bioreactor

Scientific

Microferm Fermentor
Controlled

Environment
Shaker/Incubator

Eppendorf Minispin
Centrifuge

PCR of genes
Large scale cultures

New Brunswick

Large scale cultures

Scientific
New Brunswick

Small scale cultures

Scientific
Model Number
5415

Small scale cell pellets and protein
concentration

Table 3.5: GE Life Sciences AKTA FPLC columns.
Column:

Function

Resin

Product code

DEAE Sepharose

Anion Exchange

Diethylaminoethyl

FF XK 26

Sepharose

CM Sepharose

Cation Exchange

HisPrep FF 16/10

His-tag Purification

Sepharose

28-9365-51

HiPrep 26/10
Desalting

Buffer Exchange

Superdex G-25
Superfine

17-5087-01

Gel Filtration

Superdex 75 Prep

17-1070-01

Carboxymethyl

FF XK 26

Sepharose

Column

Hiload 26/60

Superdex 75 pg
Hiload 16/60

Grade

Gel Filtration

Superdex 200 Prep

Superdex 200 pg

Superdex 75HR

17-1069-01

Grade
Gel Filtration

Superdex 75, 13 urn

17-1047-01

Crosslinked

17-5176-01

10/300

Superdex 75HR
10/300 Peptide

Gel Filtration

Agarose and

Column

Dextran, 13µp?
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3.2

Protein Production and Biochemical Studies

These projects use proteins that are produced recombinantly. A list of these
proteins and their expression vectors are found in Table 3.1. The transformation and

expression of all proteins was the same with the exception of the antibiotic, whereas

the purification was specific to the protein. Any mutants of the respective proteins
were transformed, expressed, and purified exactly the same as their native proteins.
Expression tags and proteases used to cleave them are also listed in Table 3.1.

3.2.1 Theromin Transformation, Expression, and Purification
The theromin gene constructed by Mr. Joel Lwande (Figure 3.1) was ligated
into the pET42a vector, which contains resistance to the antibiotic kanamycin (i).
The gene for theromin also had a fusion tag, glutathione S-transferase. A fusion was
made for this protein to increase both the yield and solubility of the small peptide.
The fusion also made it easier to selectively purify. A column specific to the
glutathione S-transferase tag (GST tag) was used to select for the theromin fusion
protein. The plasmid was transformed into Rosetta2(DE3) cells, exhibiting an
inherent chloramphenicol resistance. Competent cells were removed from -8O0C
storage and put directly into ice to thaw.
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1E CENTECPRACP G EYEFDEDGCN
TCVCKGCDDAQCRCSSDANGCESF

CTCNTRCSAADECNPRCTCK67
Figure 3.1: Amino acid sequence of theromin, the orange residues constitute the
negatively charged region of the peptide that is presumed to bind to the exosites. The
blue residues are the 16 cysteines used to make the proposed functional dimer.

3 µ? dimethylsulfoxide (DMSO) and 0.2 ng of plasmid (typically 1-2 µ? of a
20 ng/mL solution) was introduced to the cells, then allowed to incubate on ice for 30

min. Following incubation the cells were heat shocked for 30-90 sec at 42°C (time
depended on the volume of cells); this opens up the pores of the cells to allow the
plasmid inside. The heat shocked cells were placed back on ice to revive them. The
transformed cells were combined with 1 mL of SOC media (20 g/L bacterial tryptone,
5 g/L yeast extract, 10 mM NaCl, 2.5 mM KCl, 10 mM MgCl2, 10 mM MgSO4, 20
mM glucose, pH 7.0) and put in a shaker at 37°C and allowed to shake for 1 hr. The

cells were then centrifuged at 10,000 rpm in the Minispin Eppendorf centrifuge for 15
sec to concentrate the cells for plating. The supernatant was removed from the pellet
leaving about 100 \ih for resuspension. The newly suspended cells were spread on an
LB agar (10 g/L bacto-tryptone, 5 g/L yeast extract, 10 g/L NaCl, 15 g/L agar, pH
7.0) plate infused with 30 µg/mL kanamycin sulfate. The plate was grown in an
incubator maintained at 370C overnight.

The colonies on the plates were used to inoculate liquid LB media for growing
cultures and expressing the protein. First, four 5 mL starter cultures were made

containing 30 µg/mL kanamycin sulfate and incubated in a 37°C shaking incubator
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until the media was warm (usually about 10 min). A single colony was chosen from
the plate and inoculated into each of the four cultures; allowed to grow to an
approximate optical density (OD6oo) of 0.6-1.0 (about 1 hr), then inoculated into

respective 1 L cultures containing the same concentration of kanamycin sulfate.
From the 5 mL culture a 1 L culture was grown to an OD of 0.6-1.0 (usually 2-3 hr).
The culture was then induced to overexpress the GST-Theromin fusion protein by
adding IPTG to the media at a final concentration of 1 mM. The cells were then

allowed to grow another 6-8 hr with 1 mL samples taken every hour to run on a gel as
an induction test. Following expression, the cells were harvested by centrifugation at
3000xg for 20 min in a Sorvall centrifuge, equipped with an SLA3000 rotor spinning
at about 4000 rpm. Once collected, the pellets were either stored at -2O0C or

immediately processed for protein removal and subsequent purification.
Removal of the protein, in this case a GST-Theromin fusion protein, involved
using a Bugbuster® reagent to gently disrupt the cell membranes and benzonase
nuclease was added to break up DNA into nucleotides. The cells were suspended in
BugBuster® reagent/benzonase nuclease to 5 mL reagent and 1 µ? reagent to 1 g
pellet respectively, and shaken gently (usually 20-50 rpm) on a table top shaker for 1
hr. The cell debris was centrifuged with a Sorvall centrifuge equipped with an SS34
rotor spun at 15,000 rpm (12,000xg) for 20 min to leave the over-expressed protein

suspended in the supernatant. The supernatant was decanted and stored at 40C (no
longer than 4 hr, otherwise precipitation occurred) to be loaded on a GST-tag FPLC
column for initial purification (Figure 3.2).
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GST-Tag Affinity Column
¥

Buffer Exchange
H ¡Prep 28/10 Desalting Column

____________V
Cleavage of GST-tag
Factor Xa Cleavage

.

V
GST-Tag Affinity Column
Y
Concentrate Theromin
Amicon Device w/ 3000M WCO Filter

Figure 3.2: Purification and cleavage of GST-Theromin.

A GST-tag column containing glutathione S transferase was equilibrated with

10 column volumes (CV) (200 mL) of phosphate buffered saline at pH 7.3 (140 mM
NaCl, 2.7 mM KCl, 10 mM Na2HPO4, 1.8 mM KH2PO4) for binding the GSTtheromin and washing away the other proteins. After loading the protein, another 10
CV (200 mL) was used to wash out unbound sample. The protein was eluted with an
isocratically with 50 mM Tris buffer pH 8.0 containing 10 mM L-glutathione. The
flow rate for all FPLC processes was 1 mL/min.
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Once the protein was eluted and run on an SDS-PAGE to determine purity,
the protein was desalted using a desalting column equilibrated with Factor Xa buffer
(100 mM NaCl, 50 mM Tris-HCl, 5 mM CaCl2, pH 8.0). Up to 10 mL of protein
solution could be added to the column using an injection loop on the FPLC and eluted
at 6 mL/min. The newly exchanged protein was then concentrated to approximately
10 mL and 10 µg of Factor Xa was added per milligram protein (determined by a
Bradford assay). Typically, cleavage was performed between 16-20 hr, monitored by
a cleavage test. The cleavage test involved collecting 20 µ? of the cleavage solution
every 3-4 hr and loaded on an SDS-PAGE to determine the extent of cleavage.
Once cleavage was completed, the protein was loaded on the same GST-tag
column as before, except the flow through was collected, as the GST-tag binds and
theromin does not. The unbound theromin protein was washed from the column with
two column volumes of phosphate buffered saline (8 g/L NaCl, 0.2 g/L KCl, 1.44 g/L
Na2HPO4, 0.24 g/L NaH2PO4, pH 7.5). The theromin protein was then concentrated,
in an Amicon device equipped with a 3000 Da molecular weight cut-off (MWCO)
filter, to approximately 5-7 mL and stored at -200C.

The concentration of theromin was measured by a thiol sulfide quantification
kit from Invitrogen (T-6060). This kit uses modified papain to determine thiol
concentration in proteins. Typical protein quantification methods (i.e. BCA or
Bradford assays) aren't useful in determining theromin concentrations.
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3.2.2

Inhibition Characterization

Theromin has a direct a-thrombin inhibition characteristic that is explored
herein. The novelty of this peptide is its recombinant form, which could have
different inhibition characteristics from those reported by Salzet (2). This section
describes experiments ranging from kinetics to understanding the effect of salt on the
effectiveness of inhibition.
3.2.2.1

Theromin Inhibition Kinetics

The kinetics experiments were carried out similar to Salzet et. al. experiments
(2). They used a slow binding inhibition equation to describe a-thrombin's activity.
Equation 3.1 describes a linear representation for slow tight binding noncompetitive
inhibition kinetics, with equation 3.2 being a simplification made by Bieth (1980) (5).

£ = ^W + [P]. (« = *)

(3.2)

The terms in Equation 3.1 are /' which is a term to simplify the l-v/v0 where v, is the
rate at any given enzyme concentration, v0 is the maximum, initial rate, and E is the
enzyme concentrations bound to inhibitor I, and K, is the inhibition constant.

Equation 3.2 is a simplified variation of Equation 3.1, where "a" is another variable to
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describe the v/vo and these terms mean the same as previously. Equation 3.2 still

accounts for the inhibitor concentration, I, and inhibition constant, K/>(¥¥, (?,,a?? is the
apparent inhibition constant), and the major difference is it is also affected by P, the
concentration of product formed. Equation 3.2 is easily plotted as a linear equation
in the form of y=mx+b. The kinetics experiments were carried out on an OHs Cary
14 UV-Vis spectrometer. The rates of a-thrombin cleavage were monitored by the
cleavage of p-nitroaniline from a small modified peptide H-D-Phe-Pip-Arg. The
change in absorbance was monitored at 405nm.

The a-thrombin was prepared to a final concentration of 34.3 pM in 25 mM
Tris-HCl, pH 7.2 containing 136 mM NaOAc, 150 mM NaCl, 0.6% PEG2000, and
1% (w/w) BSA. The theromin was prepared in the same buffer and added to the a-

thrombin solution to a final concentration of 98.4 pM. The S-2238 Chromozyme was
added to the sample in different concentrations to get the specific variables for the
equation previously mentioned. The S-2238 is a short modified peptide with a pnitroanaline attached to it (H-D-Phenylalanyl-L-pipecolyl-L-arginine-p-nitroanaline
hydrochloride) that when in the presence of a-thrombin gets cleaved between the
arginine and the p-nitroanaline. The p-nitroanaline is yellow when removed from the
modified peptide, so absorbance changes were monitored at 405 nm to determine
kinetic changes in the activity of a-thrombin as theromin was added to the system.
Table 3.6 shows the experimental conditions of the kinetics experiments.
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Table 3.6: Theromin inhibition kinetics set-up parameters, all components were
made as stocks in the assay buffer.
Sample:

a-thrombin,
pM:

Theromin, pM:

1

34.3

82.0

82.0

34.3

82.0

98.4

34.3

82.0

114.8

34.3

82.0

131.2

34.3

82.0

147.6

34.3

82.0

164.0

34.3

82.0

180.4

S-2238

Chromozyme, pM:

3.2.3 Wilson Disease Protein Domain 4 Transformation, Expression, and
Purification

The Wilson disease protein domain 4 (WLN4) gene (Figure 3.1) was ligated
into the pET32Xa/LIC vector containing an ampicillin resistance gene, as well as a
Trx tag and a Factor Xa cleavage site. The transformation was done the same as
discussed in Section 2.2.1, with the exception that the transformation of

pET32Xa/LIC containing WLN4 was plated on LB agar plates containing 100 µg/mL
ampicillin. The expression of WLN4 was also the same procedure as discussed for
theromin; again with the exception of 100 µg/mL ampicillin was used instead of
kanamycin.
The Trx-WLN4 protein, once overexpressed and harvested from the cells

using a commercial reagent, and was then loaded on a HisPrep column equilibrated
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with 50 mM Tris, 20 mM imidazole, and 500 mM NaCl at pH 8.0. The nickel(II)

column was chelated by the poly-histidine tag (six histidines in a row), allowing all
other proteins to pass through. The column was washed to remove unbound protein
for 15 CV (300 mL) at a flow rate of 1 .0 mL/min. The protein was then eluted with a
linear gradient over 25 CV (500 mL) with 50 mM Tris, 500 mM imidazole, 500 mM
NaCl at pH 8.0 and the same flow rate. The gradient typically produced a very nice
sharp peak around 25% buffer B, which was Trx-WLN4 (based on SDS-PAGE). Tris
buffer was chosen for this step because the thioredoxin needs to be cleaved off, and
that is done in Factor Xa buffer which contains calcium. Typically, HisPrep columns
run with a Tris binding buffer and a phosphate elution buffer, but when the cleavage
buffer contains calcium it makes it more difficult to exchange the buffer. The
calcium in the cleavage buffer precipitates out in phosphate buffer as calcium
phosphate; this causes problems because protein will also precipitate with it.
After the Trx-WLN4 was collected, it was concentrated to approximately 10
mL in an Amicon device equipped with a 10 kDa MWCO filter. This concentrated
solution was then injected on a desalting column equilibrated with Factor Xa buffer
(See Section 2.2.1). The newly exchanged protein was concentrated a second time to
approximately the same volume for cleavage of the thioredoxin tag. The Factor Xa
was added at 10 µg per 1 mg of protein, determined by a Bradford assay, and takes
between 16-20 hr to completely cleave thioredoxin.
SDS-PAGE verified complete cleavage, and the protein was passed through
the same HisPrep column as the initial purification step to remove the tag. The
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column was equilibrated with 50 mM Tris buffer containing 20 mM imidazole and
500 mM NaCl at pH 8.0, at a flow rate of 1.0 mL/min, flow through was collected for
3 CV (60 mL) of eluent. The WLN4 protein solution was collected and concentrated
in an Amicon device equipped with a 3000 MWCO filter to 5-7 mL to be loaded on a

Superdex 75 (26/60) gel filtration column. The column was equilibrated with 2 CV
(640 mL) of 50 mM Tris containing 150 mM NaCl at pH 8.0, with a flow rate of 3
mL/min. Following equilibration the WLN4 solution was injected on the column and
isocratically eluted with same buffer at a flow rate of 2.5 mL/min; 5 mL fractions
were collected.

An SDS-PAGE was run to determine which peak contained WLN4 (elution
volume of approximately 220 mL), and those fractions were collected and
concentrated in the Amicon device equipped with a 3000 MWCO filter. The volume

was reduced to 10 mL and the protein solution was exchanged into phosphate buffer.
The exchange was done on a HiPrep desalting column equilibrated with 50 mM
phosphate buffer at pH 7.5. Finally after the buffer exchange the protein was
concentrated to 2-3 mL and quantified using a BCA assay.
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3.2.4 13C515N Double Labeled Cysteine WLN4, Transformation Expression,
and Purification

For a couple of the experiments it was necessary to make WLN4 with

cysteines that were double labeled. To do this uniformly labeled 13C,15N-L-cysteine
was purchased from Cambridge Isotopes, and incorporated into the WLN4 protein.
This procedure involved the use of specially modified BL21(DE3) CysE cells given
as a gracious gift by Marie-Paule Strub at NIH. The CysE refers to these cells having
a knock out of the serine acetyltransferase gene, which prevents these cells from
making cysteine out of glucose. This is important because these cells need to take up

and incorporate the 13C,15N-L-cysteine provided in the media. These modified cells
also have an inherent kanamycin resistance built in, which helps in to selection for
these cells. The cells were received as a culture in a cold stab medium. The cells

were then taken and plated on LB agar plates containing 50 µg/mL L-cysteine and 30
µg/mL kanamycin sulfate. The plates were stored in an incubator set at 37°C for

overnight growth. The colonies were harvested from the plates and inoculated in six
5 mL cultures containing 50 pg/mL L-cysteine and 30 µg/mL kanamycin sulfate.
The colonies were allowed to grow in a shaking incubator set at 37°C until the OD
reached 0.6-1.0, then glycerol was added to a final concentration of 20% (v/v) and
alliquoted into 2 mL cryogenic tubes which were first frozen on dry ice then moved
to the -800C freezer for storage.

Initially, the glycerol stock of BL21(DE3) CysE was used to inoculate an LB
agar plate containing 50 µg/mL L-cysteine and 30 µg/mL kanamycin sulfate, and
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grown overnight in an incubator set at 370C. These colonies were harvested and

inoculated into four 5 mL LB cultures containing 50 µg/mL L-cysteine and 30 µg/mL
kanamycin sulfate and grown in a 37°C shaker until the ODöoo was approximately
0.6. The cells were then inoculated into 200 mL LB media containing same
components, and grown to an OD6oo between 0.6-1.0 (approximately 2 hr). The cells
were then gently pelleted in a Sorvall Centrifuge equipped with an SLA3000 rotor,
centrifuged at 2,500 rpm for 10 min at 4°C. The supernatant was decanted and
discarded and the pellet dried further by wicking up the small excess of media with a
static free wipe. The pellet was then resuspended in an ice-cold solution of 80 mM
MgCl2 and 20 mM CaC^ and pelleted a second time under the conditions above. The
cells were resuspended a second time in 500 µ? solution of 100 mM CaCb. The now
competent cells were immediately put on ice and transformed with the pET32aXaLIC
vector containing the Trx-WLN4 gene.

To the competent cells was added 3 µ?, DMSO, and 1-2 µ?, (-20 ng/mL)
plasmid and left on ice for 30 min. The partially transformed cells were then heat
shocked at 42°C for 60-90 seconds and returned to the ice for 2 min. 1 mL of SOC

media was added to the transformation and it was placed in a shaking incubator set at
37°C for 1 hr. Finally the cells were centrifuged in an Eppendorf centrifuge at 10,000
rpm for 2 min and approximately 1 .3 mL of the supernatant was removed. The
remainder was used to resuspend the cells and subsequently plate them on LB agar
plates containing 50 µg/mL L-cysteine, 100 µg/mL ampicillin, and 30 µg/mL
kanamycin sulfate, and grown in a 370C incubator overnight.
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The cells made in this way typically do not have high competence, so out of a
200 mL cell culture; the number of colonies is approximately 20-50. One colony
from the plate was chosen to inoculate one of six 5 mL cultures containing the same
components as the plates they came from. The 5 mL cultures were allowed to grow

for approximately 2-3 hr (OD was -0.6). Then the culture that had the highest OD
was selected and used to inoculate a larger, 200 mL, culture identical in recipe to the
5 mL. The larger culture was allowed to grow to an OD of 0.6-1.0. Then it was
gently pelleted in the Sorvall centrifuge at room temperature. The supernatant was
decanted and discarded and 37°C water (autoclaved water was placed in the shaker to
equilibrate to 370C, so cells weren't shocked) was used to wash the surface of the
pellet and then resuspend it. The water/cell suspension was used to inoculate the M9
minimal media equilibrated to 370C. Table 3.7 contains the recipe conditions of the
M9 minimal media used for growing the BL21(DE3) CysE cells.
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Table 3.7: Recipe for M9 minimal media used in growing cells capable of

incorporating 13C, 5N-L-cysteine into their proteins. *Note the 5X M9 media was

made with the following recipe: 15g KH2PO4, 42.5g Na2HP04«2H20, 2.5g NaCl in
1000 mL milliQ water (<18O). Also all components were filtered through a 0.22 µ??
syringe filter. HCl and NaOH amino acids refers to them being dissolved in those
solutions at 0.100 N.

Component:

Concentration

M9 Media

5X*

MgSO4

IM

CaCl2

IM

Solution Q

Saturated

MEM Vitamin Mix

Saturated

HCl Amino Acids (A,
N, R, G, S, Q, H, K, P,
T, I, W, V, P, L, M)

Volume Added

to IL, mL

Notes:

200

0.3

100 mg/ 1OmL,
0. IN HCl

NaOH Amino Acids

lOOmg/lOmL,

(E, D, Y)

0. IN NaOH

13C,15N-L-cysteine

25 mg/mL in

Glucose

2g/10mL

Kanamycin Sulfate

30 mg/mL

Ampicillin

100 mg/mL

Cloudy precipitate
appears initially

Suspend the amino
10

10

acids after each

addition, they tend to
be low solubility
High solubility

0. IN HCl
10

The cells were grown in the M9 minimal media to an OD of 0.6-1.0, taking
approximately six hours. The protein expression was induced with addition of IPTG
to a final concentration of 1 mM. The cells were allowed to express of 8 hr, at which
time they were harvested in a Sorvall centrifuge and stored at -2O0C. Extraction of
the protein and subsequent purification was done as described in Section 2.2.2.
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WLN4 was concentrated to approximately 1 mM in 50 mM phosphate buffer pH 7.5
for NMR analysis.

3.2.5 15N WLN4 Transformation, Expression, and Purification
Transformation, expression and purification were performed the same for the
C, N-L-cysteine protein expression, except for one change. This expression used

15NIItCl, and didn't require the individual amino acids as these could be made from
glucose, NH4CI, and sulfate.

The cells used for the transformation were

Rosetta(DE3) cells from stocks stored at -8O0C.

3.2.6 15N and Native Isotope HAHl Transformation, Expression, and
Purification

HAHl is expressed from the vector pETl Id-HAHl (ampicillin resistant).
The transformation and expression is done in an identical fashion to the
pET32aXa/LIC (Trx-WLN4). The differences are in the purification.

The cells are treated with a freeze-thaw technique that gently opens the
membranes to let the protein out. The cells are frozen on liquid nitrogen (77 K) for 5
min, then they are thawed under cold water for 35 min, and the cycle is repeated 3
more times. Following the final freeze-thaw cycle, 240 mL extraction buffer (20 mM
MES, 1 mM EDTA at pH 5.5), is added to the pellet. The pellet is suspended in the
extraction buffer and gently shaken for 1 hr. The cell solution is then pelleted again
in a Sorvall centrifuge equipped with an SS34 rotor, centrifuged at 15,000 rpm for 20
min. The supernatant, containing the protein was decanted into a Falcon 50 mL
conical tube, and stored at 4°C.
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The first step in the purification process used the pi of HAHl (-7.5). This pi
made this protein positive near physiological conditions (pH -7.5), and it could bind

to a cation exchange column. Most proteins in a cell are either hydrophobic or
negative, very few are positively charged. HAHl was loaded on a tandem set-up of a
anion exchange column (DEAE) followed by a cation exchange column (CM) (refer
to Table 3.4 for column details), equilibrated with 20 CV (~1 L) binding buffer (20
mM MES, pH 6) at a flow rate of 2 mL/min. The DEAE column was used as a trap
to bind most of the proteins in the supernatant solution, leaving a cleaner protein
solution to allow binding to the CM column. There were also many proteins that flow

through both columns and don't bind to either. After the HAHl protein solution
loaded on the columns, 20 CV (-1L) binding buffer was used to wash out unbound
sample from the columns. The columns were then disconnected and the HAHl was
eluted from the CM column. Elution involved a linear gradient over 10 CV (-500
mL) of elution buffer (20 mM MES, 1 M NaCl, pH 6) at a flow rate of 2 mL/min.
The HAHl was detected with SDS-PAGE and pertinent fractions combined.
The HAHl solution was then concentrated on an Amicon device equipped

with a 3000 MWCO filter to approximately 20 mL (this protein expresses with very
high efficiency so the volume isn't highly reduced at this point). The concentrated
HAHl solution was further purified by a Superdex75 (26/60) gel filtration column

equilibrated with 50 mM phosphate buffer containing 150 mM NaCl at pH 7.5.
Following this purification step the HAHl was >95% pure, determined by SDSPAGE, and reverse phase HPLC.
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3.2.7

NMR Studies of the Intermediate Interaction Between WLN4 and HAHl

NMR studies were performed in collaboration with Ivano Bertini' s group at
the Center for Magnetic Resonance (CERM) in Florence, Italy. All measurements

were conducted on Bruker Avance NMR Spectrometers at 1H nominal frequencies of
500, 600, 700, and 800 MHz, and were equipped with cryogenically cooled probes.
The experiments were double resonance techniques to detect chemical changes and
mobility changes due to perturbations in the chemical environment, and ultimately in
an interaction of the binding partners via copper(I).
After the proteins were expressed and purified, they were concentrated to
nearly 1 mM, determined by Biorad or BCA assays. The labeling was of the mutant
protein, this was to prevent any detection of homodimerization that could give a false
positive as an interaction. The mutant protein was placed in an NMR tube in a Vac
Atmospheres glove box equilibrated with nitrogen and maintained at <1 ppm O2. The
protein was reduced under a nitrogen atmosphere with 1 mM dithiothreitol (DTT).

An initial 1H-15N HSQC spectrum was measured of the apo, unbound mutant. Then
the binding partner was titrated in to a 1 : 1 ratio (determined via peak heights in the
IH NMR spectrum pertaining to well resolved isoleucines on both proteins). All

NMR measurements were done at 300K (4). A 1H-15N HSQC spectrum was
measured after each addition of respective native partner, this ensured there was no
interaction in the absence of metal (5). Once a 1:1 ratio was measured of the two
proteins, copper(I) was added [as tetrakis(acetonitrile) hexafluorophosphate
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copper(I)] under the same nitrogen atmosphere. The copper(I) was titrated into the
solution in approximately 10% increments until a 1:1 ratio was achieved between the
proteins in solution and the copper(I). The ratio was determined comparing the

copper(I) concentration to one of the proteins in solution. All 1H-15N HSQC spectra
were collected on a Bruker Avance 700 MHz NMR equipped with a cryoprobe.
Interactions were detected by chemical shifts in the 2D spectrum. However, shifts are
not totally indicative of interaction, and mobility was used to be certain. Mobility
gives information as to how fast a molecule, peptide in this case, is tumbling in
solution. Ultimately, larger objects tumble slower than larger ones, so a monomer
will tumble significantly faster than two proteins interacting with each other.
Once all spectra were collected the average chemical shifts of the peaks (each
peak representing an amide pertaining to one amino acid) was determined to illustrate
the extent of changes in the chemical environment around the binding site. To do this
the chemical shifts are compared using Equation 3.3 (CSV is Chemical Shift
Variation, where ?d is change in chemical shift for the respective nucleus) (6).

CSV = J

(3.3)

Mobility experiments were done on a Bruker Avance 600 MHz spectrometer
equipped with a cryoprobe. Dynamics of the apo and titrated forms of the proteins
were measured using techniques described by Ishima et. al. (7). Basically, relaxation
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measurements are taken of Rl (longitudinal, Z2-axis) and R2 (transverse, XY-plane),
based on 15N-mutant relaxation rates (5, 8). Tl and T2 are calculated using model
free analysis software. The ratio of these rates can be correlated to the estimated
tumbling time of a protein in solution. These rates are mass dependent, allowing for a
distinctive difference between a monomeric protein and a complex in solution.
3.2.8

UV-Vis Titrations of WLN4-HAH1 Intermediate Interaction

The intermediates were also titrated together in the presence of copper(I) and
other various similar, or at least tighter binding, metals [i.e. Ag(I) and Cd(II)]. The
proteins were prepared as described in Section 2.2.3, and the buffer used in all
titrations was 50 mM sodium phosphate buffer at pH 7.5. This buffer was used to be
consistent with the NMR experiments.
The apo protein was prepared in the cuvette at a known concentration;
typically two different concentrations were used, 5 mM and 20 mM. The lower
concentration was used to detect metal to ligand charge transfer (MLCT) bands below
220 nm as the protein backbone absorbs in these regions and will overshadow any
MLCT bands. The higher concentration of protein will give more distinct MLCT
bands around 250-300 nm (253-261 nm should be a 2-coordinate) (9, 10) species and
a bathochromic shift toward 270-300 (10) indicates a higher coordination species.
Protein preparation was done in the Vac Atmospheres nitrogen glove box using
degassed 50 mM phosphate buffer. The phosphate buffer was prepared and degassed

with a Schlenk line equipped with a vacuum and argon. The phosphate solution was
evacuated of oxygen for approximately 10 min with subsequent equilibration with
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argon. This cycle was repeated for 1 hr with simultaneous sonication to remove

dissolved oxygen. The buffer was then moved into the glove box for storage.
The native protein was then titrated with a 1 mM copper(I) solution that was
prepared by addition of tetrakis(acetonitrile) hexafluorophosphate copper(I) to
degassed milliQ water containing 10% acetonitrile. The stock copper(I) solution was

prepared by degassing 500 mL milliQ water (<18 O) on a Schlenk line equipped with
a vacuum and ultra high purity argon. The solution was then moved into the nitrogen
atmosphere Vac Atmospheres glove box. A copper(I) complex was measured and
diluted with the degassed water containing 10% (v/v) acetonitrile. This solution was
capped with a septum and wrapped with parafilm to prevent oxygen contamination.
The cuvette was removed from the glove box and measured initially on the
Olis Cary 14 UV-Vis spectrometer equipped with a split beam and a water jacketed
cuvette holder. A second similar cuvette containing the same degassed phosphate
buffer was put in the blank cuvette location to get simultaneous blank subtractions
during each measurement. Once a blank measurement was determined (to remove
the spectrum from the protein itself), the copper(I)-acetonitrile solution was titrated in
(typically at 10%, substoichiometric, increments). The copper(I) solution was added
to both the experimental cuvette and the blank cuvette, and measurements recorded.
Once titrations reached a 1:1 ratio of native proteinxopper(I), the mutant partner was
titrated in. The mutant solution was prepared similar to the native protein except the
concentration was five times higher as to not have a huge dilution effect. The dilution
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effect was accounted for by dividing all spectra by the concentration of native protein,
as it changed with changes in volume in the cuvette.

3.2.9 HAHl 199Hg(II) NMR
The HAHl was prepared as described in Section 2.2.6. The 199HgCb was
added to half an equivalent to facilitate a dimerized mercury(II) species if one could

exist, and spectra were collected at various pHs. The 199Hg(II)HAHl was prepared in
phosphate buffer at 150 mM for pH values 7.5 and 8.5, and 200 mM CHES was used
for pH values 9.4, 9.8, and 10.2.

The spectra were collected at room temperature on a Varian Inova 500 MHz

spectrometer tuned to 89.48 MHz for 199Hg and equipped with a 5 mm broadband
probe (70). The reference used was a 0.1 mM Hg(ClO4^ solution made in a 0.1 mM
HCIO4/D2O solution, and measured at -2250 ppm (11). The samples were prepared
under a flow of argon by adding 10-15 mg HAHl to a 15% solution OfD2O, and the

concentration of protein was determined by Ellman's test. The Hg(II) was then added

as 199Hg(NO3)2 in appropriate amounts to equate to one-half equivalent based on
protein concentration. A stock solution of 91% isotopically enriched 199HgO was
obtained from Cambridge Isotope Laboratories (12), where mercury(II) oxide was
dissolved in hydrochloric acid and the pH was adjusted for NMR studies. The pH
titrations were done with either HCl or KOH.
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3.2.10 lwmHg(II) Perturbed Angular Correlation (PAC)
Perturbed angular correlation experiments were conducted to determine the
coordination environment around the Hg(II). These experiments were done at the
ISOLDE GLM beam line at CERN (Geneva, Switzerland). The protein was prepared
by resuspending lyophilized HAHl into either 150 mM phosphate buffer (pH 7.5 and
8.5) or 200 mM CHES buffer (pH 9.4, 9.8, and 10.2). The final concentration was
approximately 20-50 uM.
150 uL water was added to a Teflon cup and frozen with liquid nitrogen, then
mounted on the ISOLDE GLM beam line in a vacuum chamber. The frozen water

was then infused with radioactive l""1Hg(II) (has two gamma photons given off,
t'/2=43 min and second gamma photon given off 2.3 ns following 1st) over 1 hr. The

199mHg(II) was prepared by irradiating liquid lead with 1 GeV photons, then using a
mass separator to select for the proper isotope.
The ice, mounted on the beam line, was thawed slowly (approximately 10
min) in a fume hood and under argon to prevent condensation of water vapor from the
air. Mercury (II) chloride was added to the thawed water, followed by the appropriate
buffer, and finally the protein. The pH was then adjusted since the temperature of the
measurements was 1°C, the pH was adjusted for temperature dependence using the
website: http://www.liv.ac.uk/buffers/buffercalc.html, left to equilibrate for 10 min,
and finally sucrose was added to 55%. The sucrose was added to slow the tumbling
of proteins due to Brownian motion.
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The PAC instrument consisted of a 6-detector PAC camera set-up, and data

collection and analysis was done with Prelude and Winfit software, developed by
Butz et. al. and using a standard chi-square algorithm (11). An adjustment was made

using a 199mHg(II) sample to make sure both ?-photons were given off to the same
channel. Each nuclear quadripole interaction (NQI) was modeled using a different set
ofVq, ?, d, Vt0. and A parameters. Equation 3.4 describes the parameter that describes
the strength of the electronic environment and the mercury nucleus. Q represents the

electronic dipole moment around the nucleus and Vzz represents the largest
eigenvalue of the electric field gradient tensor.

eQVzz

Vq = -^

(3.4)

The parameter ? represents the asymmetry of the system (a value of 0 is used in any
axially symmetric system, and values can range up to 1 in a highly asymmetrical
system), d is the relative frequency spread, tc is the rotational correlation time, and A

is the amplitude of the signal (11, 12). Important to note, vQ doesn't directly account
for the spectrum obtained from PAC so another parameter is introduced cui
representing the location ofthe 1st peak in the Fourier transform.
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3.2.11 Hg(II)HAHl Aggregation State by Gel Filtration
One final study of the Hg(II)HAHl coordination studies was to determine the

aggregation state at the various pH values; this may give information as to whether
the different coordination states are monomeric or dimeric. Gel filtration can be used

as an analytical method to determine apparent sizes of proteins due to differences in
hydrodynamic radii. The radius of the protein is somewhat indicative of its molecular
weight; the larger the protein the larger its hydrodynamic radius.
The Hg(II)HAHl was prepared by purifying the HAHl as described in

Section 2.2.6. The HAHl was then concentrated to approximately 500-1000 µ?
using ultrafiltration and 1 mM DTT added and allowed to reduce at room temperature
for 30 min. The DTT was then removed using a PDlO buffer exchange column (into
either the phosphate buffer or the CHES buffer). The protein was concentrated a

second time, concentration determined using a BCA assay, and split into two samples
(apo and metallated).

The apo sample was injected on an AKTA FPLC equipped with a HRl 0/30

gel filtration column, equilibrated with 3 CV (approximately 72 mL) of the proper
buffer and pH (Table 3.8).
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Table 3.8: Buffer composition for each pH of the Hg(II)HAHl gel filtration studies.
Note: all buffers were degassed/filtered prior to use, and the pH was adjusted for
temperature dependent changes (studies done at 4°C).
Buffer (pH):
Phosphate Buffer (7.5)

Composition:
100 mM Pi buffer (Na2PO4, and

Phosphate Buffer (8.5)

100 mM Pi buffer (Na2PO4, and

NaH2PO4), 200 mM NaCl

CHES Buffer (9.4)

NaH2PO4), 200 mM NaCl
25 mM CHES, 100 mM NaCl

CHES Buffer (9.8)

25 mM CHES, 100 mM NaCl

CHES Buffer (10.2)

25 mM CHES, 100 mM NaCl

The flow rate for these studies was 0.5 mL/min, and samples were collected in 0.5
mL volumes. The apex of the peak was determined to be the elution volume of the

protein, which was determined using the Unicorn software provided with the AKTA
instrument.

A calibration curve was made at each of the pH values to get an appropriate
mass independent of the buffer and pH used. Calibration of the column starts with an

injection (25 µ?) of a high molecular weight molecule, Blue Dextran. This polymer
is large enough to not interact with any of the stationary phase and can be used as an
indicator of the void volume (the volume which solutes that don't interact with the

stationary phase elute). Next an injection of a 10% (v/v) acetone solution (50 uL) is
run to determine the bed volume (total mobile phase volume of the column). The

acetone is very small and will interact many times with the stationary phase. These
two initial calibration injections give the usable volume of the column, or the volume
where solutes would elute. The Blue Dextran elution volume (v0) and the acetone
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elution volume (?,) are used for the calculation of the standard curve. The standard

curve is made of a linear plot of the K^ (partition coefficient) vs. the log MW. A plot
of elution volume vs. molecular weight would give a sigmoidal curve with
asymptotes pertaining to solutes that are too large or too small for the resolution of

the column. To account for the nonlinearity of the plot, a new term, Kav, is used.
This term takes into account the void volume, the bed volume and the elution volume

so this value becomes linear in comparison to the molecular weight. Equation 3.5
describes this relationship in order to determine the apparent molecular weight based
on a set of standards.

T,

ve-vQ

Kav = i~ir

(3·5)

The calibration curve was made by injecting 100 uL of a mixture of standards
made by mixing 25 uL of each stock protein solution. Table 3.9 shows the standards
and their masses. The standards were injected as a mixture and eluted as a cluster of

well-defined peaks. The Unicorn 5.0 software was again used to determine the apex
of each of the peaks.
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Table 3.9: List of calibration standards used on the HRl 0/30 gel filtration column to
determine apparent molecular weights of the different aggregation states of apo and

Hg(II)HAHl.

Calibration Standard:

Molecular Weight (Daltons):

Aprotinin
Cytochrome C

6,600
13,700
29,000

Carbonic Anydrase
Albumin

43,000
2,000,000

Blue Dextran

Figure 3.3 depicts a typical standard curve plot for calibrating the HRl 0/30 gel
filtration column with the standards described in Table 3.9. After the calibration

curve is calculated, the apoHAHl and Hg(II)HAHl protein was injected on the
column with exactly the same conditions as the calibration curve (i.e. buffer and flow
rate).
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y = -2.47x + 5.12

Figure 3.3: A typical plot used to determine a K^v value that corresponds to an
apparent molecular weight.

Preparation of the Hg(II)HAHl was done by adding one-half equivalent
HgCl2 to the protein solution. ???µ? was injected on the column and ran at a flow

rate of 0.5 ml/min. The apex ofthe peak was determined using the Unicorn 5.0
software, and calculated against the calibration curve to get the apparent mass. All
apparent molecular weights were determined as described, changing only the buffer
and pH of the mobile phase.
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CHAPTER 4

BIOCHEMICAL PROPERTIES OF THEROMIN: A NOVEL THROMBIN
INHIBITOR

4.1

Introduction

There has been a lot of attention placed on discovering better anticoagulation

therapies for patients. Currently the most common anticoagulant drug is heparin.
Heparin is a sulfated glycosaminoglycan, that the body naturally produces to help
maintain the blood in a fluid state or help stop clotting when necessary (1). Heparin
works by binding to the inhibitor antithrombin III, this further increases its inhbiting
abilities. The complex then can go on to inhibit many enzymes of the clotting
cascade responsible for creating a clot, specifically, Factor Xa and a-thrombin (2, J).
This study focused on another a-thrombin inhibitor, theromin, which was

isolated from the leech Theromyzon tessulatum by Salzet et al. (4). In their study,
theromin was found to be a strict tight binding a-thrombin inhibitor with a K, = 12
fM. This value is stronger than that obtained with hirudin (5-7)) and haemadin (100
fM) (S)) under similar conditions. Theromin monomer had little a-thrombin

inhibition, leading them to suggest that dimerization is necessary to give the peptide
an active structure configuration for complete binding to a-thrombin. The way this
was discovered was to use a reducing agent on the theromin peptide to maintain it in a
monomeric state and determine its K1-. The reported K, was significantly higher for
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the monomer than they measured for the dimer. Salzet also reported the monomer
has some anti-a-thrombin activity. This idea led to the suggestion that each monomer

binds to one of the exosites and blocks both active sites by wrapping around as a
dimer. Theromin has no significant sequence similarity to other a-thrombin

inhibitors. Theromin exists as a homodimer of 134 residues (important to note there
were no post translational modifications to the peptide, this is in contrast to hirudin

which has a sulfated tyrosine at residue 63 (P, 70)), each monomer containing 16
cysteine groups that form 8 disulfide bonds which would be important in creating its
dimeric structure. It binds to a-thrombin denying access to both the fibrinogen site as
well as the proteolytic site. Detailed understanding of the folding mechanism of
theromin is likely to contribute vital information necessary for development of new
anticoagulants. Due to its potential biomedical importance, there is need for further

characterization of the recombinant theromin. A comparison should be drawn
between the reduced and the oxidized forms then compared to hirudin. To carry out
further studies on theromin, it is necessary to devise an easier and faster way of
getting large amounts of the protein. A previous master's student, Joel Lwande (11),
successfully designed and synthesized the theromin gene through the PCR
amplification method and subsequently expressed the protein in E. coli and purified
it. The a-thrombin binding affinity for the recombinant theromin, K/, was determined.
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4.2

Recombinant Expression of Theromin

31kDa
24kDa
17kDa
12kDa

Figure 4.1: SDS-PAGE of theromin after 16 hours of cutting. Top arrow
indicates the oxidized dimer of theromin (supposed active form), and bottom arrow
shows the faint band of the monomer form.
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The plasmid, pET42a, was transformed into Rosetta2(DE3) cells. The protein
overexpressed by this plasmid was a 3OkDa peptide of Glutathione S-Transferase
tagged theromin (GST-theromin). The purification involved initially selecting for the
tag using a column equipped with glutathione that can bind the tag, the protein was
washed with several column volumes of buffer and eluted with a gradient of up to 10
mM glutathione. The elution from the GST-Tag column exhibited one peak that
contained the fusion protein. The protein was then exchanged into Factor Xa buffer
for cleavage; this was accomplished using a buffer exchange column. The exchanged
protein was concentrated to approximately 10 mL and the concentration of the tagged
protein determined and Factor Xa was added to 10 µg/mg protein (typical yield was
about 20 mg of tagged protein in a liter prep). The cleavage was performed for 16 hr,
monitored by SDS-PAGE. The protein was then loaded on the same column
equipped with glutathione to remove the tag, leaving a pure theromin peptide that was
7.2 kDa in size observed by SDS-PAGE, there was also some oxidized dimer, at 14

kDa on the gel (Figure 4.1). This size of protein was similar to what Salzet noticed
in the native form (4).
4.3

Theromin Inhibition Kinetics Toward a-Thrombin

The activity of theromin was monitored indirectly by measuring the rate of
chromozyme S-2238 cleavage, both with and without theromin.
( i ?

L = EJ+ K1 yl-ij
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(4.1)

V

Voy

Equation 4.1 describes measuring the activity of a-thrombin at various inhibitor
concentrations and then correlating each [I]/(l-v/v0) vs l/(v</v;), where v, is the rate at
each inhibitor concentration, v0 is the vmax rate, and [I] is the inhibitor concentration.
This correlation comes from a derivation by Henderson (12), which was further
simplified by Bieth (13). The relationship comes from an assumption theromin is
acting as a noncompetitive tight binding inhibitor (described by Salzet in ref. 5); this
would mean that theromin doesn't compete for the active site, rather it binds to an
allosteric site (in this case either or both of the exosites), which alters the state of the
protein preventing substrate binding. The determination of the binding kinetics was
based on hirudin, which binds to exosite 2 and causes an allosteric inhibition of the

active site. Theromin is expected to do the same type of inhibition because Salzet
suggested theromin wraps around a-thrombin. This wrapping event would cause

allosteric changes throughout a-thrombin that could further enhance the binding of
theromin. There is, however, no evidence yet for this.
The enzyme, in a noncompetitive inhibition model, can be described as

existing in four distinct states: [E], [ES], [EI], and [ESI], in the case of several direct
a-thrombin inhibitors that interact in a tight binding fashion the ESI complex is very
low concentration or possibly even non-existent. Theromin fits the description as a
very tight binding inhibitor, so a very small amount would be presumed in the ESI
form. This allows for elimination of this factor from the kinetics equation and leaves
the kinetics only dependent on the different reaction rates (v0 and v„ where the V0 is
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the rate in the absence of inhibitor and v, is with inhibitor added) and the inhibitor
concentration.

Plotting [I]/[l -(Vv0)] vs [v</v¿\ yields a linear correlation appears where KUapp
can be calculated from the slope. Theromin was analyzed in this manner to determine

the ??,a??. The peptide was added to the a-thrombin and allowed to equilibrate for 10
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Figure 4.2: The slope of the line is the Kitapp, which is 13.5 fM, compared to the
?,,a?? for the native peptide. The r2 value of the line is 0.97.
minutes before substrate was added; this was sufficient time to allow the peptide to
bind to a-thrombin and most likely eliminate the possibility of an ESI complex.
Figure 4.2 shows the resulting curve from the kinetics experiments. The slope of the
plot is ?,a??, which was calculated to be 14.9±8 fM, which is in agreement with what

has been published by Salzet (2001) of 12±5 fM. The K, is an average of three assays
that gave inhibition constants: 24.1 fM, 13.5 fM, and 7.2 fM. It seems based on

comparison of inhibition, and mass spectrometry analysis by Salzet that there are no
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modifications of the peptide in the leech, since the masses match up and both peptides
exhibit the same inhibition capacity.
Theromin isn't the only direct a-thrombin inhibitor to date drugs such as
Ximelagatran {14, 15). This drug is a small organic molecule that can be taken orally
as a prodrug, which is converted in the liver and other tissues to the active form,
melagatran.

This conversion involves dealkylation and dehydroxylation.

The

proposed advantage to this drug is that it can be taken orally, and more importantly, it

doesn't require constant monitoring of the blood coagulation time. This is a major
advantage due to issues with patient compliance with taking their medicines. Another

direct a-thrombin inhibitor, dabigatran, is considered to be superior to the drug
warfarin in preventing stroke {16). This drug is also a prodrug that is converted to its
active form by an esterase in the blood serum {16). It has the same advantages as
ximelagatran does, with the exception that less of the dabigatran is bioavailable (20%
for the Ximelagatran compared to 6.5% of the dabigatran). These drugs have
inhibition constants of 4.5 nM for dabigatran {17), and 2 nM for Ximelagatran {18).
While these drugs look to be promising, they have significantly lower
inhibition constants for a-thrombin than does hirudin (current drug Lepirudin®) (21
fM), and the newly discovered theromin (14.9 fM). The disadvantages of the new,
stronger, direct a-thrombin inhibitors is they currently need to be interveinous. This
would also be the likely route of entry for theromin, if it were to go to FDA approval.
These types of strong direct a-thrombin inhibitors need to be monitored very closely,
which is a disadvantage compared to ximelagatran and dabigatran. Not only do the
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latter two drugs not need to be monitored, but they can be taken orally. These are two
very important factors when considering a drug candidate. This poses the idea that

these drugs need to be modified in some way to be taken orally and then possibly
modified so they could be taken without constant monitoring.

Direct a-thrombin inhibitors seem to be the direction research has been going.
They are much more efficient and more easily controlled than inhibitors to factors
upstream of a-thrombin in the blood coagulation cascade.

One example is

Coumadin® (also referred to as Warfarin), the way it inhibits is the enzyme epoxide
reductase which then interferes with the production of vitamin K (19, 20). This
prevents blood clotting because vitamin K is important for post-translational
modifications of proteins that create prothrombin (Factor II), the precursor to active
a-thrombin (19). It also is required for production of coagulation Factors: VII, IX,
and X (19, 21). This single inhibition has a very wide range of effects on the blood,
requiring the need for constant monitoring and initial drug dose changes to get the

proper dose based on body mass. This is a huge disadvantage for this drug, even
though it is very effective. There are other issues, mentioned in Chapter 1,
associated with another indirect inhibitor heparin. Briefly, this drug forms a complex
with platelet Factor 4 and can activate antibodies to it through and autoimmune
response. The tail of this antibody can activate platelets causing a secondary clot to
form.

So direct a-thrombin inhibitors are very important to maintaining the blood in

a fluid state, with few disadvantages as compared to historically used drugs.
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Theromin is a strong direct a-thrombin inhibitor that can inhibit very efficiently.
There is still a lot of characterization needed for theromin to get it close to being a
drug candidate, as it is necessary to understand how it reacts with the other
components in the blood. One observation was that it resembles metallothioneins and

could possibly bind copper(I), so theromin might have multiple functions and cause
many problems as a therapy for clot prevention.
4.4

Copper Binding Studies
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Figure 4.3: Titration of copper(I) into theromin. Theromin exhibits a
metallothionein-like primary structure. Titration was up to 9 equivalents, based on
ICP-AES measurements of copper(I) standards. The slit widths used were 5mm for
both excitation and emission.
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Theromin's main function seems to be its ability to bind a-thrombin and
inhibit it with great efficiency.

Structurally, however, it has a remarkable

resemblance to metallothioneins (22). This was noted by its arrangement of the 16
cysteines within its structure and was tested by titrating copper(I) into it. It is not
clear, however, if this is a function of the peptide, or if it is a method for protecting
the peptide from proteases when being injected into the host.

Metallothioneins are low molecular weight peptides that are full of cysteines
with the ability to bind different metals. In particular cadmium (23, 24), zinc (25),
and copper (26). These metallothioneins are suggested to be involved in preventing
heavy metal toxicity within cells (27). It wouldn't seem theromin is working with the
ability to bind heavy metals, but that might be a role in the leech itself.
Figure 4.3 shows the fluorescence of the copper(I) thiolates at an excitation of

290 nm. The emission is around 615 nm, which is similar to what Fujisawa noted for
aliphatic copper thiolates (he described a peak at 618 nm for an aliphatic complex
containing 5 eq copper) (28). The titration was stopped after the emission plateaued,
which turned out to be around 7 eq based on ICP-AES analysis done in Dr. Carla
Koretsky's lab at Western Michigan University. This is a novel find for this peptide,
copper(I) binding hasn't been shown for any of the other similar peptides, for
example hirudin, but maybe be a good model system for metallothioneins. Even
though it is shown here copper(I) binds, it is still not known what the clusters look
like.
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Figure 4.4: Azide titrations into copper(I) theromin to determine strength of
copper(I) binding. Azide in excess of 50 equivalents isn't sufficient to pull copper(I)
out of theromin. Excitation was at 290 nm. Brown: 0 eq azide, red: 16.7 eq azide,
orange: 20 eq azide, yellow: 26.7 eq azide, and green: 50 eq azide.
Following the titrations of theromin with copper(I), it was important to
determine what the binding affinity was. To do this sodium azide was titrated in up
to 3 µ???? (essentially 50 eq of azide to 1 eq copper) (Figure 4.4). The azide had
very little effect on the copper(I) bound to theromin. One chelator that wasn't tried

was cyanide, this is a very strong chelator for copper(I). For this reason cyanide is
very deadly, as it can pull copper out of the respiratory proteins in the mitochondria.
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4.5

Conclusion

Theromin shows a lot of promise for being a strong inhibitor to a-thrombin, it
can bind and inhibit a-thrombin with an inhibition constant of 13.5 fM which is

significantly stronger than the latest direct a-thrombin inhibitor hirudin (-21 fM).
There is a need for stronger inhibitors to a-thrombin that can be easily regulated in
therapies to prevent clotting. Currently the most widely used drug is heparin which in
some patients can actually cause an autoimmune response to the heparin/a-thrombin
complex that will activate platelets and cause clots. Recently, hirudin has been used
as an alternative to heparin for this reason, it is a very effective drug, however, and it
has to be tightly monitored because it can cause bleeding events.
Theromin's ability to bind copper(I) seems an unlikely characteristic in vivo.
This is would be the case for two reasons, in the blood copper is available as
copper(II), and not copper(I) and the affinity of this oxidation state of copper would

be much lower due to hard soft acid base (HSAB) theory suggesting copper(II) would
much rather bind to something like the nitrogen groups of histidine rather than the
sulfides of cysteines. This attribute of theromin could have functionality in the leech

itself though, but many more studies would need to be done to determine that aspect.
A second reason copper(I) binding is unlikely in vivo is that even if there were to be
copper(I) available for binding, the affinity would need to be low enough that there

isn't competition between copper and a-thrombin. If the binding affinity of theromin
for the metals in the blood were higher than the affinity for a-thrombin, then the leech
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wouldn't be able to maintain the blood in a fluid state, independent of the host and
would essentially die off.
4.6

Future Studies

There are many experiments that could be done to understand both what this

peptide does in the host as well as what it does in the leech. The main experiment

that could to be done as an independent verification of the peptide we were working
with. A second verification would be to do N-terminal sequencing, giving us a
stronger idea of the peptide we are measuring. This peptide does not behave well at

all, but with the idea that it can bind copper, maybe a mass of the copper loaded
peptide can be determined. Based on previous work the native protein didn't have
any post translational modifications. It does beg the question to how the leech stores
and maintains a stock ofthis peptide.
Other experiments would be biophysical in nature, using EXAFS and NMR.

It would be interesting to determine what the copper(I) clusters look like using
EXAFS, we could also titrate in cadmium(II) and do cadmium- 1 13 NMR. The latter

experiment would give more of a quantitative idea of the copper(I) thiolates that exist.
It would also be interesting to determine which cysteines are involved in the binding

ofthe copper(I) this could be done by NMR, selective labeling of the cysteines might
give information about the assembly of the clusters in the Cu(I)theromin. It would
also be interesting to determine if other metals can bind, such as zinc(II).
Further experiments involving the interaction with a-thrombin would be

mutational analysis to determine if mutating certain residues makes a stronger hold on
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a-thrombin resulting in a stronger inhibition constant. Again NMR could be done,
C, N labeling a-thrombin and titrating in theromin could give structural

information as to how theromin binds. It was suggested that it binds initially to
exosite I and wraps around similar to a Ziploc® seal around to exosite II. There is no

evidence for this except that the peptide likes to be a dimer outside the leech, this may
just be an inherent feature of the protein in vitro and not something that occurs in
vivo. Understanding how theromin works could shed light on why hirudin can bind
strongly and not need to wrap around to the other site to be a strong inhibitor. It was
shown by Salzet that the dimer was, at least in vitro, how the peptide interacts with a-

thrombin. It would be interesting to see if this is the case in vivo. One way to do this
would be to develop NMR methods for looking at whole blood and selecting for athrombin in some way.

A few experiments that would be interesting on the leech would be to

determine how the peptide is made and stored. This would give insight into
understanding how to keep this peptide in working shape. In our studies the peptide
did not hold up well on its own, it degraded within a day or two, so if we could
understand how the leech makes and protects the peptide, we could do the same.
Again, the copper(I) binding does this serve a purpose in the leech, like a
multifunctional peptide? It would not be wrong to expect the leech to have

metallothioneins, so what is the evolutionary idea behind making this peptide. The
dimer of theromin doesn't utilize all the sulfides so it is possible they are needed to
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mediate the wrapping of theromin around the a-thrombin. Mutation studies would
give solid evidence to this idea.

Overall there is a lot of work that can be done on this peptide to understand its

function in the host and its possible alterior role in the leech itself. These types of
experiments could be done to determine new models and new functions of

homologous proteins (for example theromin seems to be a homolog to
metallothioneins).
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CHAPTER 5
THE INTERACTION OF WILSON DISEASE PROTEIN METAL-BINDING
DOMAIN 4 WITH HAHl

5.1

Introduction

There have been many studies, as noted in Chapter 2, looking at the Wilson
disease protein and its interaction with its metallochaperone HAHl in humans (1, 2).
This interaction is a complicated interaction because of the individual characteristics

of the N-terminal domains. To date the constructs investigated are WLN2 (4), WLN4
(I1 5), WLN3-4 (7), WLN4-6 (6), WLN5-6 (7), and WLNl -6 (2). Each of these
various constructs gives vital information, as well as provide varying data, suggesting
that the whole N-terminal domain works in concert and removing some of it strongly
affects the behavior of the protein. One example of this is comparing the work done
on the WLNl -6 with WLN5-6. When domains 5 and 6 are alone Cu(I)HAHl doesn't
seem to have any interaction with it, neither in the form of complex nor in copper(I)
delivery (7). However, when WLN1-6 was investigated there was an interaction with
WLN5-6, in the form of copper delivery, but no appreciable complex between
WLN5-6 and Cu(I)HAHl could be detected.
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Figure 5.1: A model put together by Dr. David Huffman, Dr. Ivano Bertini, and Dr.

Simone Ciofi depicting a possible electrostatic interaction between the positively
charged HAHl and the negatively charged WLN4.
There is still quite a bit to learn from these different interactions; one part of
the puzzle that still needs to be investigated is the mechanism of the hand-off between

the Cu(I)HAHl and the different metal-binding domains of WLNP. Only three ofthe
metal binding domains (WLNl, 2, and 4) can create an appreciable NMR-observable

complex with Cu(I)HAHl. In the case of the WLN3, 5, and 6 there is no complex
formation detected, and they are in slow exchange on the NMR timescale. There is
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however, one domain that seems to be an excellent choice for determining this
mechanism, WLN4. WLN4 (pi 3.9) is a highly negative domain, in contrast to
HAHl (pi 7.5) that is highly positive. On an NMR timescale this interaction,
mediated by copper, is observed, possibly due to strengthened interaction via
electrostatics. Figure 5.1 shows a model developed by David Huffman, Simone

Ciofi, and Ivano Bertini depicting the possible interaction between these two proteins.
In light of this strong interaction, WLN4 and Cu(I)HAHl have been chosen to
determine the mechanism for copper delivery from the chaperone to the domains of
WLNP. One study used computer modeling to show the interaction between these

two proteins, and found that there are two different 3-coordinate species that may
exist during the hand off (8). To determine if these types of intermediates could be

formed, mutants were made where individual metal-binding cysteines of either
WLN4 or HAHl were mutated (9-11). These mutated proteins were then titrated

with the wildtype partner and copper(I) to determine whether a complex could be
found between them. This idea is very similar to the work by Banci et. al. with the
ATX1/Ccc2a system in yeast (3). ATXl is the yeast homolog to HAHl and Ccc2a is
the yeast ATPase homolog to WLNP. Their data showed that one cysteine from each
of the binding partners could be mutated and still facilitate an NMR-observable

complex. Data from this project found that both cysteines are necessary in the WLN4
domain to facilitate a complex formation, and only cysteine- 12 of HAHl was
necessary.
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5.2

Wilson Disease Protein Domain 4 Expression and Purification

Figure 5.2: SDS PAGE showing a highly pure cleaved WLN4.
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The WLN4 was expressed as a thioredoxin fusion protein with the vector
pET32Xa/LIC. Expression and purification methods were described in Section 3.2.3.
The induction was monitored by 15% SDS-PAGE.

Once the induction was

determined successful, the protein was purified using a HisPrep column to select

TrxWLN4, followed by several buffer exchanges and concentration events to get it

31kDa
24kDa
17kDa

12kDa

Figure 5.3: SDS PAGE showing pure HAHl protein.
into Factor Xa cleavage buffer. The protein was cleaved for 18 hr at room

temperature. After cleavage the protein was run through the HisPrep column again
and subsequently concentrated using ultrafiltration and run through a gel filtration
column to get purified WLN4 (Figure 5.2).
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All purifications of the different isopically labeled or mutant WLN4 proteins
were done the same way. The only differences lie in the expression procedures, noted
in Section 3.2.3- 3.2.5.

5.3

HAHl Expression and Purification
HAHl was expressed using the vector pETl Id-HAHl. The details of the

expression and purification are detailed Section 3.2.6. The induction was again
monitored using 15% SDS-PAGE. The purification for HAHl was quite different
from WLN4, mostly due to not having a thioredoxin tag and it being positive (pi
around 7.5). The purification involved connecting a DEAE and CM column in

tandem and using MES buffer, pH 6.0. The DEAE column was first, collecting most
of the bacterial proteins, as they are negatively charged. The CM column then picked
up the HAHl that was eluted as a single peak on the chromatogram. The fractions

containing the HAHl were collected and concentrated to be run on the gel filtration
column to be sure of their purity (Figure 5.3). Following the gel filtration the protein
was highly pure and ready for experiments. Again, these gels represent the native
HAHl purification, but the purification of the isotopically labeled and mutated HAHl
exhibited exactly the same characteristics, so gels and purification methods were the

same. The only difference being the methods for expressing the protein (Section
3.2.6).
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5.4

NMR Titrations of WLN4 with HAHl and Copper(I)
To investigate the possible intermediates involved in the mechanism of

transferring copper to the WLN4, mutants were made of each of the proteins to be

titrated together and analyzed using 1H-15N HSQC on a Bruker Avance NMR at
either 700 MHz or 800 MHz at the Center for Magnetic Resonance, Florence, Italy.
Each titration started out with 1 mM, labeled, mutant protein. The mutant protein
was labeled to prevent detection of homodimerization that could give a false positive

for interaction between the species. Two spectra were collected, a 1H (proton), and a

1H-15N HSQC, the proton spectrum was collected to monitor the amide protons,
making sure were still folded correctly (monitoring peak distributions), and to
monitor the proline protons as a method for knowing when the titration reacted a 1 : 1

ratio for the protein. The temperature of these experiments was 300K. During the

titration of the apo proteins, the 1H-15N HSQC was monitored for any shifts in the
spectra due to interactions that weren't metal mediated. During the HSQC titrations,

the native protein was titrated into the NMR solution containing the mutant. For all
experiments there was no detectable interaction between the mutant and the native
binding partner in the absence of metal. There was, however, one titration (C15A

HAHl/wtWLN4) that did show some small shifts in the 1H-15N HSQC in the absence
of metal, but when EDTA was titrated in the shifts moved back to the original
positions. It was suggested that there was contamination of a divalent metal, most

likely zinc(II), as this is a common metal and previous experiments had seen such
contamination before, in the Bertini lab. The set up of the experiment was such that
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metal mediated interaction could be monitored. Table 5.1 shows list of the titrations

done. Studies prior to this work have described the interaction of HAHl with the

various domains of WLNP. A recent study that mentioned a possible interaction
between the domains in the absence of copper(I), however, there was up to 8% copper
in the buffer solution, so the evidence was not substantiated (J).

Table 5.1: The NMR experiments used to monitor the titration using 1H and 1H-15N
HSQC.

Exp.

Description:

Protein:

Titrant:

Number:

1 ID Proton Spectrum

apoC15AHAHl

ID Proton Spectrum

apoC15AHAHl

ID Proton Spectrum

apoC15AHAHl

ID Proton Spectrum

apoC15AHAHl

ID Proton Spectrum

apoC15AHAHl

1H-15N HSQC
1H-15N HSQC

1H-15N HSQC
1H-15N HSQC
9
10
11
12
13
14
15
16
17
18
19
20
21
22

1H-15N HSQC

ID Proton Spectrum

apoC15A

1H-15N HSQC

HAH1/WLN4

ID Proton Spectrum

apoC15A

1H-15N HSQC

HAH1/WLN4

ID Proton Spectrum

apoC15A

1H-15N HSQC

HAH1/WLN4

ID Proton Spectrum

apoC15A

1H-15N HSQC

HAH1/WLN4

ID Proton Spectrum

apoC15A

1H-15N HSQC

HAH1/WLN4

ID Proton Spectrum

apoC15A

1H-15N HSQC

HAH1/WLN4
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Va eq apoWLN4
V2 eq apoWLN4
Va eq apoWLN4
1 eq apoWLN4
Va eq copper(I)
Vi eq copper(I)
Va eq copper(I)
1 eq copper(I)
1 Va eq copper(I)
1 1A eq copper(I)

Following the proteins being titrated to a 1:1 ratio, copper(I) was titrated in
under a nitrogen atmosphere chamber as a solution of tetrakis(acetonitrile)copper(I)
hexafluorophosphate to a 1:1, protein:copper(I). The copper(I) was obtained from a
10 mM stock solution prepared in 100% deuterated acetonitrile.
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Figure 5.4 shows the spectrum overlay of apoWLN4 (blue) with Cu(I)WLN4
(red). There are many peaks that shift which are very close to the binding loop. It is
important to note, not all peaks shift in the spectrum; if that were the case then it

would be reasonable to expect that the folding of the protein was affected by the
copper(I) binding. We see no effect on the structure due to copper(I) coordination,
which is in agreement with the published data (1, 5).
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Figure 5.5: A 1H-15N HSQC overlay of 15N Cl 5A HAHl before addition of
CuWLN4 (red) and after (blue). The ratio of C15A HAHl:Cu(I):WLN4 was 1:1:1,
however the titration was done past the 1:1:1 ratio and no further chemical shifts were
observed.

Figure 5.5 shows a zoomed overlay of the WLN4/copper(I)/C15A HAHl titration;
depicting the most pertinent peaks that exhibit the highest chemical shift and even
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some that disappear due to copper binding near them. Not all peaks in the spectrum
are accounted for due to the unavailability of a double labeled sample. The peaks that
are labeled are of the 15N-C15AHAH1
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Figure 5.6: 1H-15N HSQC of 15N C12A HAHl (green) titrated with Cu(I)WLN4
(blue). Ratio of C 1 2A HAH 1 :Cu(I):WLN4 was 1 : 1 : 1 , titration of copper past 1:1:1
was also done (not shown) and didn't show any further shifting ofthe peaks.
Figure 5.6 shows the C12A HAHl titration overlay with selected peaks
labeled. As can be seen from the spectrum, there are many peaks that shift, however

this spectrum exemplifies the idea that shifts in the HSQC aren't necessarily
indicative of an interaction. To determine whether there is interaction between two
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proteins, it is imperative to determine the mobility of the proteins before and after the
titration.

Mobility measures the tumbling time of a protein in solution. Proteins in a
solution are dynamic and can rotate freely. This rotation is dependent on size and
shape. The tumbling time is the time it takes a protein to rotate 1 radian. Table 5.2

shows a typical set up for the mobility experiments. To determine the mobility there
are two experiments that need to be done, one involving relaxation times along the Zaxis (called longitudinal relaxation or Ti) and the other of relaxation times in the XYplane (called transverse relaxation or T2). The relationship between these two times

is T2<Ti. The relaxation rates were measured using pulse sequences described by
Farrow (1994), with refocusing times as described in Table 5.2 (12). Water was
suppressed using a "water flip-back" scheme (13, 14).
Table 5.3 shows the tumbling correlation times from the different

experiments performed. Mobility was done on all combinations of wildtype protein
and mutated partner. The table predicts that only the C15A HAHl could facilitate
complex formation with wtWLN4 in the presence of copper. The others didn't show
a significant change in mobility from the apo monomer compared to what could be
the complex. This is different from what was published for the yeast ATXl:CCC2a
system. That data suggested that one of the cysteines could be mutated in each of the
binding partners and still create a complex. Our data shows both cysteines need to be
present in WLN4 to create a complex. This would be expected due to the fact that

WLN4 seems to be one of the most stable domains, further suggesting it is a rigid
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structure that can't accommodate, or can't efficiently accommodate loss of one of the
cysteines.

Table 5.2: Typical delay times used to determine the relaxation rates.
Longitudinal Relaxation
Experiments,Ti; ms:

Traverse Relaxation Experiments, T2, ms:

2.5

16.96

35

33.92

75

50.88

125

84.80

200

118.72

370

186.56

500

220.48

675

271.36
152.64

1.5

305.28
322.24
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Table 5.3: Compilation of the tumbling times for the different titrations done.

Species:

Tumbling

nanoseconds, -rm

Cu(I)HAHl (5)

4.6 ± 0.4

apoWLN4/Cu(I)HAHl (5)

7.2 ±0.7

apoC18AWLN4

4.3 ± 0.4

apoC18A WLN4/Cu(I)HAHl

4.4 ± 0.4

apoC15AWLN4

4.8 ±0.3

apoC 1 5A WLN4/Cu(I)HAH 1

ND

apoC12AHAHl

3.6 ±0.2

apoC12A HAHl/Cu(I)WLN4

3.9 ±0.4

apoC15AHAHl

4.1 ±0.4

apoC15A HAHl/Cu(I)WLN4

7.6 ± 0.6

apoC18AATXl (3)

4.1 ±0.7

apoC 1 8A ATX 1 /Cu(I)Ccc2a

5.7 ±0.6

(3)

5.5

time,

Interaction

YES

VERY LITTLE/NONE

NONE

VERY LITTLE/NONE

YES

YES

NMR Technique to Investigate Protein Interactions
NMR has become a powerful technique to determine solution behaviors of

proteins. NMR has been used to determine conformations in solution through 1H-15N
HSQC measurements (15). Marcellus Ubbink's group has done a lot of work with
NMR to look at the various interactions between protein partners (15-18). One
specific study used paramagnetic NMR to investigate the interaction of cytochrome c
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and cytochrome c peroxidase (75). This study was similar to this work in that they
were mutating cysteines to determine the effects to the backbone and the interaction

of the two proteins. Certain mutations caused perturbations in the protein backbone
that resulted in disappearance of peaks in the HSQC. These disappearances indicated
more flexibility in the backbone and in some cases perturbed the interaction between
the two proteins. These types of interactions can be seen in other protein systems as

well, for example the WLN4/HAH1 and Atxl/Ccc2a interactions. 1H-15N HSQC
experiments have been used on both of these systems to investigate perturbations in
the backbone due to either copper(I) binding or interaction with the binding partner.
5.6

Yeast Homolog System: Atxl/Ccc2a
The interaction of the yeast homolog to HAHl, Atxl can deliver copper to the

ATPase Ccc2. Ccc2 has two cytosolic metal binding domains that can accept copper.
This work was done in comparison to titrations of Atxl with the first metal-binding
domain Ccc2a. Currently there are solution structures of both the copper(I) bound
and apo forms of Atxl (19) and Ccc2a (20). An interesting feature of the Atxl
protein is that when copper(I) is bound, the metal-binding cysteines take on a buried

conformation and upon release of the copper the metal-binding cysteines become
solvent accessible (19, 21). The Atxl behavior is in contrast to the HAHl because

HAHl has its copper(I) bound cysteines in a solvent accessible position (22).
Many similarities in the copper transport system between yeast and humans
has led to a comparison of them. Previous work on the Atxl/Ccc2a system revealed
there are no overall changes in the structure upon interaction with the binding partner,
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this was a supported finding in the WLNP/HAH1 interaction as well (1, 2, 5).
Following the native interactions, attention turned to the mechanism of how the

copper(I) was delivered from the metallochaperone to the respective metal-binding
domain on the ATPase. In the Atxl/Ccc2a system mutations were made to each of
the metal binding cysteines in order to trap a possible intermediate (3). Figure 5.7

shows the 1H-15N HSQC data obtained from the titration of various mutations to the
Atxl/Ccc2a metal binding cysteines . Comparison of panel A and B of Figure 5.7
(Ccc2a/Atxl titration) to Figures 5.6 and 5.5 (WLN4/HAH1 titration) respectively,
they both represent a complex formation when the most buried cysteine is mutated,
but can't facilitate interaction when the solvent accessible cysteine is mutated. Panels
C and D of Figure 5.7 indicate the difference between the yeast system and the
human WLN4/HAH1 interaction. In the WLN4 mutants there was no interaction

when either of the mutants were titrated with Cu(I)HAHl (Table 5.3). However, in
the yeast system the Ccc2a could facilitate an interaction when cysteine 16 was
mutated (most buried metal-binding cysteine). This suggests WLN4 is a much more
rigid domain that may not be dynamic enough to facilitate an interaction. This could
be substantiated in the fact that the WLN4 domain is the most stable of all the

domains (23).
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Figure 5.7: A. C15A Atxl (green) titrated with wtCcc2a (red), B. C18A Atxl
(green) titrated with wtCcc2a (red), C. wt Atxl (green) titrated with C13A Ccc2a
(red), D. wt Atxl (green) titrated with C15A Ccc2a (red). All titrations were done in
the presence of 1 eq copper(I) with respect to the Atxl protein (3).
5.7

UV-Vis Titrations of the WLN4:HAH1 Interaction in the Presence
of Copper(I)

While NMR is the most informative way to determine complex formation
there are other ways to detect it. The most convenient way is to do UV-Vis titrations.

One protein is concentrated and exchanged into degassed buffer in a nitrogen
atmospheres glove box. This protein is then measured initially on an Olis Cary 14
spectrophotometer to get an initial blank reading. This is necessary to remove any
absorbance coming from the backbone of the protein and the intrinsic chromophores
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within it, such as tryptophan, tyrosine, and disulfide bonds. The range of the
measurement is from 600-190 nm in 1 nm increments. Starting out at 600 nm is a
good way to determine if there is baseline shifting due to inaccurate additions or
differences in the measurements, as the interaction should have no absorbance that

close to the visible region. The interaction was monitored using two cuvettes, one for

the blank and one for the measured sample. This too is important because there may
be interactions of the titrants with the buffer or other material that could give baseline
shifting or false positives.

O Eq Cu(I)

0.16 Eq Cu(I)
0.33 Eq Cu(I)
0.49 Eq Cu(I)
0.66 Eq Cu(I)
0.82 Eq Cu(I)
0.98 Eq Cu(I)

-0.05

200 225 250 275 300 325 350 375 400 425 450 475 500
Wavelength, nm

Figure 5.8: UV-Vis titration of copper(I) into apoWLN4 to nearly one equivalent.
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Copper(I) was not the only metal used to do the titrations; they were also done
with cadmium(II) and silver(I). This was in attempt to find a metal that could
facilitate a strong interaction and could be detected using gel filtration studies.
Figure 5.8 shows the titration curve of copper(I) addition to WLN4; as
expected there is a peak that starts to form at around 266 nm which would be due to
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Figure 5.9: Titration of CuWLN4 with the mutant C15A HAHl to one equivalent.
Cu(I)WLN4 was titrated with increasing amounts of C15AHAH1. Green: 0.16 eq,
yellow: 0.39 eq, orange: 0.71 eq, and red: 1.04 eq.
the formation of a 2-coordinate copper complex. Fujisawa made models trying to
understand how the metal to ligand charge transfer (MLCT) bands change with
varying metal coordination (24). His data suggested that a 2-coordinate copper(I)
complex would exhibit a MLCT at around 254 nm which would then move out to
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closer to 300 nm as the complex became 3-coordinate (24). This is similar to what is
observed here, 5.9 shows a peak forming at 266 nm which can be attributed to a 2coordinate copper(I) thiolate complex. It isn't quite the 254 nm described by
Fujisawa, but his data was from models (24).
Once copper(I) was titrated into the WLN4, C15A HAHl was titrated in.
Figure 5.9 shows the titration after addition of C15A HAHl. The new feature of this

titration is the appearance of the peak at 280 nm which would suggest a higher
coordinated state of the copper. At this point the coordination state of the metal can't

be determined, but it seems it has shifted. Also the peak at around 266 nm has
disappeared, indicating that the 2-coordinate state has been changed. The shift in
MLCT band suggested a change in coordination state due to addition of the C15A

HAHl. This data corroborates the NMR data, which also showed a complex
formation between these two binding partners.

There were many experiments for the other binding mutant interactions,
where the copper bound wildtype protein was titrated with the mutated binding
partner (refer to Table 5.3 for titrations done).

For all titrations except the

WLN4/Cu(I)/C15A HAHl there was no MLCT bands indicative of complex
formation. These findings also corroborate the NMR data, where no complex
formation was detected for any of the other titrations.

137

0.11 EqC15AHAH1
0.22 Eq C15A HAM
0.34EqC15AHAH1
0.45EqC15AHAH1
0.56EqC15AHAH1
0.67EqC15AHAH1
0.78EqC15AHAH1
0.89EqC15AHAH1
1.01 EqC15AHAH1
1.12EqC15AHAH1

0.18
0.16
0.14

< 0.12
?

?

m

0.1

S 0.08
U)

< 0.06
0.04
0.02

210

260

310

360

Wavelength, nm

Figure 5.10: 66.5µ? Cd(II)WLN4 was titrated with the mutant Cl 5A HAHl. This

was done to find a metal that would hold the complex together better than copper(I).

Gel filtration analysis was also used to detect the complex formed. This
technique uses several well-behaving standards to determine the size of a protein that
moves through the column. Each protein has a particular hydrodynamic radius that
allows it to move through a gel filtration column and elute at a particular elution
volume. The elution volume is dependent on several factors, the buffer and pH, the
size of the protein, the size of the medium in the column, and the flow rate. The

Cu(I)WLN4/C15A HAHl complex doesn't hold together well as it is run through the
Superdex75 gel filtration column (Figures 5.11-5.14).
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Figure 5.11: apoWLN4 elution profile from a high resolution gel
filtration column. Elution volume was 14.0 mL.
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Figure 5.12: apoC15A HAHl elution profile from a high resolution gel
filtration column. Elution volumes were 14.2 mL, 16.4 mL, and 17.2
mL.
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Figure 5.13: Cu(I)WLN4 elution profile from a high resolution gel filtration
column. Elution volumes were 7.2 mL (inside the void volume) and 14.0 mL.
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Figure 5.14:

Cu(I)WLN4/C15A HAHl elution profile from a high

resolution gel filtration column. Elution volumes were 15.4 mL and 18.48
mL.
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Comparing Figures 5.11-5.14 indicates there is something happening in the

interaction that isn't detected in the individual proteins. SDS-PAGE analysis was
done but couldn't resolve WLN4 from C15A HAHl. The best way to do this would
be to have antibodies to either of the binding partners and do Western blotting, or do
a mass spectrometry analysis on each of the fractions to determine what species is
present.

So other metals were titrated into the WLN4/C15A HAHl interaction to find a

metal that could hold the complex together well. Two particular metals were tried,

the first was cadmium(II) which doesn't mimic copper(I) very well, but has a higher
affinity for sulfides than copper(I). Figure 5.10 shows the titration of the C15A

HAHl titrated into Cd(II)WLN4. There is a definite feature that appears around 245
nm that would account for a cadmium(II) thiolate complex. This complex seemed
promising, but didn't fare well when run on the Superdex75 gel filtration column. It
seemed the complex is still labile enough that the elution profile exhibits at least 3
peaks, most likely each monomer one with copper and one without, as well as the
complex (data not shown). This data is, however interesting because future work

could look at using 113Cd(II) NMR to probe the coordination state of the complex.
Another more recent technique would be to do lllmCd(II) perturbed angular
correlation (PAC) (25, 26). Briefly, the metastable lllmCd(II) gives off two gamma
radiation events to get back to the native isotope. As the nucleus spins there is an
angle difference that can be measured between the first gamma radiation and the

second. The electronic environment around the nucleus has a large impact on the tilt
141

of the nucleus and therefore the Larmour frequency, so the more tilt the slower the
rotation and the smaller the angle between the gamma radiation events. The different
angles can then be compared to model systems and a coordination of the cadmium

determined. This is a very complicated technique for this, but would give very
interesting information.

The most used technique for determining coordination is extended X-ray
absorption fine structure (EXAFS). In this technique the sample is exposed to x-rays
starting just before the absorption edge (the energy where the electrons of the metal
absorbed the radiation). The absorption edge is indicative of the metal being probed,
so this makes the technique selective. During the EXAFS measurements, the core

electrons in the metal are excited by the x-rays and interact with the surrounding
electrons (for example the electrons of a sulfide in the case of cysteines bound to a
metal), if the electron is considered a wave in this case there is interference between it

and the surrounding electrons that can be measured at the synchrotron. This
interference pattern can then be interpreted using many different techniques and
compared to known model systems to determine coordination state of the metal in the
protein.

The interaction of Cu(I)WLN4/C15A HAHl was analyzed by X-ray
Absorption Near Edge Structure (XANES) and EXAFS (Figures 5.15-5.17)
techniques in Professor Jim Penner-Hahn's laboratory at the University of Michigan
by postdoctoral fellow Jay Stasser. In Figure 5.16 the pre-edge features around 8980
eV are where the coordination can be distinguished (27).
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Figure 5.16: k-weighted EXAFS data, Red line is the theoretical data, and blue
is the experimental, the fit is very poor.
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R + a (A)
Figure 5.17: Fourier transforms of the Cu(I)WLN4 (blue) and 3:1 C15A
HAHl:Cu(I)WLN4 interaction (red).

O'Halloran et. al. described the copper(I) coordination around Atxl using EXAFS
and XANES (28). Atxl exhibits a 3-coordinate geometry noted by a weak shoulder
around 8984 eV (28). In Figure 5.16, the WLN4 trace has a sharp shoulder around
8984 eV that is weaker WLN4/Cu(I) /C15A HAHl interaction. The weakening of the
shoulder may be indicative of a 3-coordinate state. Figure 5.17 is the Fourier
transform of the EXAFS data. It looks like the two traces are very close with some
extra features present in the Cu(I)WLN4 trace (blue), that aren't present in the
Cu(I)WLN4/HAH1 trace (red). Finally, Figure 5.16 is the raw EXAFS data that is

overlaid with a theoretical trace. The traces in Figure 5.16 don't match up very well,
making it more difficult to attribute the data to one type of coordination geometry.
Table 5.4 indicates a poor fit ofthe EXAFS data, that can be seen in the raw fitting of
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the traces in Figure 5.17. This makes it difficult to describe the coordination

environment around the copper(I) in these proteins. However, the XANES data does
suggest there is some 3-coordinate character present based on previous work with
Atxl (28). NMR is a powerful technique, but it isn't efficient enough to determine
the coordination state of metals in solution.

Table 5.4: EXAFS fit results. N is the coordination number, R is the bond length, s2
is the Debeye-Waller factor, E0 is an energy offset to match the traces in Figure 5.17,

and F is the mean-square-deviation between data and fit.
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Figure 5.19: Favored intermediate model based on NMR experiments.

5.8

Conclusion

The data here suggests the copper delivery from HAHl involves an
intermediate where there is no binding to cysteine residue 15 of HAHl, but the other
cysteines in the handoff are necessary for proper complex formation (Figure 5.18).
Based on XANES data, it is possible there is a 3-coordinate intermediate formed, as
the shoulder at around 8984 eV is smoothing, which is indicative of a 3-coordinate
species, and the radii in the fit data (Table 5.3) are consistent with a 3-coordinate

species. Previous work, with computer modeling, has shown there is a 3-coordinate
intermediate formed with both the WLN4 and the HAHl providing two of the
ligands. This is contrary to our in vitro findings in this project. The NMR data
suggested there was complex formation based on chemical shifts in the 1H-15N
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HSQC, and mobility experiments that showed a definite increase in tumbling time for
the complex compared to the apoWLN4 (Table 5.3). This mobility data turns out to
be the most important data because as was depicted in Figure 5.11 there were

chemical shifts detected in that interaction (C12A HAHl with Cu(I)WLN4), and they
seemed to be in the proper areas for an interaction, but the mobility (Table 5.3),
showed otherwise. It would have been inconceivable for the C12A HAHl interaction

to occur because the cysteine at residue 15 is more buried and would therefore be

unlikely to interact well with the Cu(I)WLN4 on its own (Figure 5.19). Figure 5.19
is the best fit model. The other mutant titrations, however, C15A and C18A WLN4

didn't show any chemical shifts in the HSQC at all, and the only one that was
measured for mobility was the C18A WLN4/Cu(I)HAHl interaction. As alluded to

previously, this is quite novel compared to the yeast system (ATXl/Cu(I)/Ccc2a) (J).
In that system at least one cysteine from each of the metal-binding partners could be
mutated and a complex formed, whereas the HAHl/Cu(I)/WLN4 system needs both

of the cysteines in the WLN4 and the cysteine at residue 12 in the HAHl. This might
be what would be expected because in the yeast system Ccc2 has only two metal
binding domains that may need to have flexibility in their function. The Wilson
disease protein has six metal-binding domains that seem to have evolved to have
specific duties. This is evident by the data that suggests domains 1,2, and 4 can form
an NMR observable complex with HAHl, whereas domains 3, 5, and 6 cannot, rather

they can accept copper from HAHl without accumulation of complex (2). This may
or may not be what is observed in vivo because there are many different experiments
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that show different binding characteristics of the different domains. The WLN4

seems to be one of the most stable of the domains (23), which could be disrupted
significantly when a cysteine was mutated to alanine. For these, and other reasons,

the WLN4 could be expected to act differently than the Ccc2a system.
Overall, the WLN4/Cu(I)/HAHl complex seems to involve at least one

intermediate involving both cysteines of WLN4 and C 12 of HAHl. There might be a
second intermediate that is very labile and can't be detected on the NMR timescale

involving one of the cysteines of WLN4. This interaction would be very hard to
detect with the current techniques. One possible way to do this would be to get a
crystal structure. This could force and maintain an interaction between the two

binding partners that could then be structurally analyzed.
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CHAPTER 6

BIOPHYSICAL CHARACTERIZATION OF MERCURY(II) HAHl USING
PERTURBED ANGULAR CORRELATION, MERCURY(II)-199 NMR,
AND GEL FILTRATION STUDIES
6.1

Introduction

HAHl is a copper chaperone that has the ability to bind other metals such as
zinc(II), cadmium(II), and mercury(II) via its two metal binding cysteines. The
affinity for these metals is mercury(II) > cadmium(II) > zinc(II) (7). For many years
the method for determining mercury structures was to make models and collect

mercury- 199 NMR spectra. Mercury- 199 has a spin of V2 making allowing it to
exhibit sharp peaks indicative of various coordination geometries (2). O'Halloran et.
al. (1995) published work using mercury-199 NMR to understand its binding to a
regulatory protein MerR (S). MerR is a regulatory protein that binds mercury(II) with
a very strong selectivity, even when presented with other metals or other competing
ligands (2-4). Once mercury(II) binds, MerR induces expression of the mercury
regulation proteins (3-5). Previous work with the MerR protein indicated it was a 3coordinate geometry based on models containing the same bond lengths compared to
EXAFS data (6). A lot of interest has involved understanding how heavy metals are
regulated.

Another protein CueR is a highly selective copper(I) regulator in E. coli cells
(7, 8). It is found in the MerR family of proteins and which includes MerR (4) and
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ZntR (a zinc regulatory protein) (9). Copper is only necessary at the concentration of
about 10 µ? (P, 10) in E. coli, and the sensitivity of CueR is in the zeptomolar range

(IO"21 M) (8). The CueR activates CopA, an ATPase similar to Wilson disease
protein or Menkes protein. Interestingly CueR has high selectivity toward gold,
silver, and copper, but has no response to either zinc or mercury (7, 11-13). So it is
important to understand the binding of the various metals to these proteins. This

gives insight as to how these proteins are selecting out metals at such great efficiency,
one distinctive feature resulting in selectivity of CueR for copper(I) and not higher
valent species. This is a residue in the N-terminous of the dimerization helix that
either interacts with the binding loop (CueR) or with the bound metal (ZntR) (8). In
the case of the MerR homologs selective for metals in the +1 state, i.e. copper(I), this
is a serine, and for MerR homologs selective for metals in the +2 state, i.e.
mercury(II), it is a cysteine (8). Another fact is that metals in the +1 state prefer

lower coordination states than do the +2, CueR facilitates this selectivity by sterically
and electrostatically controlling the coordination environment, whereas the MerR
homologs that prefer the +2 state use more solvent accessible ligands (8).
Understanding the structural features of the many proteins involved in
regulation of heavy metals in the cells is important. This gives insight as to how the
different attributes of the protein regulate the coordination environment, and in turn
controlling which metals it selects.
This study was to look at how the mercury(II) interacts with the HAHl, as far
as coordination and geometry.

Previous work on an Hg(II)HAHl homodimer
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indicated a 3-coordinate species with a possible distorted fourth coordinating thiol
(14). This fourth coordinate was at a distance that was too far for a covalent bond
(14).

Recently, the Pecoraro group synthesized peptides that can bind metals and
used various techniques to understand the metal coordination. One such peptide is

the TRI peptide that is a synthetic alpha helical peptide that is capable of binding one
mercury(II) atom per three helices. The geometry around the mercury is trigonal and

resembles the binding found in MerR (15). The geometry around the trimer of alpha
helices can be held together by various metals, including mercury(II) and
cadmium(II) (16). To study these interactions a fairly new technique, perturbed
angular correlation, was used to determine the ligand environments. This technique
has been used on the TRI peptides and found that as the pH is increased, the metal
favors a higher coordination state (16, 17).

The TRI studies (16-20) have led to the idea that other Hg(II) coordination
environments can be determined where other techniques have fallen short (i.e. UV-

Vis spectroscopy and NMR). Specifically, in Hg(II)HAHl X-ray chrystallography
studies weren't able to completely elucidate the coordination environment around the

mercury. Also, the crystal structure may not reflect how the system behaves in

solution. The goal of this project was to monitor mercury(II) coordination changes as
a function of pH. This will provide information not only about coordination
environments that are allowed, but also give information to the coordination of
mercury at physiologically relevant pH values. This study used mercury(II)-199
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NMR, mercury(II)-199m PAC, and gel filtration studies to determine the aggregation
state of the proteins in the presence of mercury(II).
6.2 Mercury(II)-199 NMR

348 ppm
pH 9.4

-348 ppm

-806 ppm
pH 8.5
819 ppm

pH 7.5
-200

-400

-600

-800

-1000

Chemical shift (ppm)

Figure 6.1: 199Hg(II) NMR spectra at the various pH values, indicating a change in

the coordination environment around the mercury(II).

Initial detection of Hg(II)HAHl complexes in solution was done by 199Hg
NMR experiments. As the pH was increased there were definite changes in the

chemical shifts (Figure 6.1). At physiological pH (-7.5) the 199Hg(II) NMR revealed
a single peak around -818 ppm which coincides with the chemical shift values
obtained from 2-coordinate mercury(II) species (21, 22). O'Halloran's group showed
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a single chemical shift at -821 ppm indicative of a 2-coordinate mercury(II) thiolate
species (22). When the pH was increased to 8.5, a second complex appears with a
chemical shift of -348 ppm. This chemical shift seems to fall within the range where
4-coordinate aliphatic mercury(II) thiolates are observed (-300 ppm to -500 ppm) (5).
MerR has a 3-coordinate environment and has chemical shifts around -106 ppm (22).
The range for a 3-coordinate mercury thiolate is -80 ppm to -160 ppm (22). Figure
6.1 shows a 4-coordinate species emerging at pH 8.5 which becomes exclusive at the

higher pH. This new peak isn't so easy to attribute to a particular geometry, and it
doesn't account for any distorted 4-coordinate species identified in the Hg(II)HAHl
dimer. Very little data is available for distorted geometries, as they are very difficult
to mimic as aliphatic models. There are other techniques developed to elucidate these
types of geometries, such as perturbed angular correlation.

6.3

199mHg(II) Perturbed Angular Correlation
199Hg NMR is insufficient for the determination of the symmetry around the

mercury(II) thiolates. Perturbed angular correlation (PAC), however, can provide this
information, as long as the metal can exist as a metastable isotope. Briefly, PAC
works by measuring the gamma radiation given off by a metal that has two distinctive
energies of radiation (refer to Section 3.2.10 for more information). The metal, in

this case, mercury(II)-199m generated from liquid lead irradiated with IGeV of
energy for 1 hour, is put in the instrument that has many detectors at different angles.
Some groups have shown that platinum metal will work for the production of

199mHg(II) as well (23). The spin of the nucleus (199mHg(II) has a spin of 13/2) is
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affected by the electronic environment around it, so in essence the coordination will

affect the tilt of the nucleus and therefore change the frequency. The frequency of
spinning is called the Larmour frequency, which ultimately dictates the angles of
gamma radiation detected. To get information about the coordination environment

models were developed and measured to get signature spectra to use in comparison.
HAH1 pH titration
8

pH 7.5
pH 8.5
pH 9.4
pH 9.8
pH 10.2
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Figure 6.2: Raw data of the PAC experiments. The most important features to note
is the decrease of the peak at around 1.4 rad/ns, and the increase at around 0.5 rad/ns.

The increased feature was best fit for a distorted 4-coordinate mercury(II) thiolate
species that increases as the pH is increased.
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The PAC experiments were done using the same pH values used in the
mercury(II) NMR experiments with the addition of a couple of values higher than pH
9.4. Table 1, along with Figure 6.2, shows the species detected at the different pH
values. When the pH is below 8.5 the PAC experiments give one signal, with vq
about 1.43 GHz and low ? (< 0.15). This signal compares well with literature data for
a linear S-Hg-S structure. At higher pH values (>9.0) the major peak still occupies the
same position but its amplitude drops by about one third. In the same spectrum a new
peak appears at lower frequency, accounting for the loss of signal in the major peak.
The pKa of the observed transition is around 8.5. This new signal can be fitted in two
different ways, either with low or high ?. The best fit is achieved with the parameter
set with low ?, but it is only slightly better than the fit with high ? (Table 6.1). This
lower frequency and the relatively large ? indicates most likely a highly distorted
four-coordination geometry. These results are in relatively good agreement with
Hg NMR experiments which show the presence of only one resonance at pH 7.5
and two resonances at pH 8.5. A further increase in pH displays the presence of two
signals. However, the amplitude of the high coQ NQI systematically drops, whereas,
the amplitude of the low coqNQI systematically increases (the high and low ooq refers
to the frequencies in Figure 6.2.
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Table 6.1: Parameters fitted to the PAC-data. The numbers in the parenthesis are the

standard deviations of the fitted parameters, oqìs the frequency, d is the relative
frequency spread, Tc is the rotational correlation time, A is the amplitude of the
signal, and y¿ describes the fit of the Fourier transform.
pH

HAHl/

H

d
100

[µ81]

A
100

3Cr'

1/tc

Hg(II)

[rad/ns]

7.5

2:1

0.223(3)

0

4(2)

40(23)

14(1)

0.65

8.5

2:1

0.223(3)f

0.150(57)

0.054(8)f 0.738(110)

7(3)
350(163)

40(80)

13(6)
1(9)

0.91

9.4

2:1

0.223(3)f 0.095(181)
0.054(8)f 1.0(799)

11(9)
17(55)

81(138)

9.8

2:1

0.223(3)f 0.258(38)
0.054(8)f 0.447(320)

9(3)
22(36)

17(40)

11(2)
6(2)

0.85

10.2

2:1

0.223(3)f

5(4)
22(22)

88(159)

8(3)
6(3)

0.70

0.054(8)

0.152(96)
1(0)

10(3)

4(3)

0.82

* Two different possible fits are presented; the two upper ines represent one (with
low frequency signal having low ?) and the two lower lines represent the other (with
low frequency signal having high ?).

The partial NQI of thiolate bound species to Hg(II) was estimated from PAC data

recorded for the known structure of Hg(Cys)2, with Oq= 1.41 GHz and with a Hg-S

bond lengths of 2.34 Â, giving ?3 - 0.705 GHz. This was used to predict the trigonal
[Hg(Cys)3]" giving uq = 1 .06 GHz in good agreement with the experimental value of

1.16 GHz. This indicates that the Bauer's axially symmetric independent ligands

(BASIL) model might be a good model for 199mHg PAC (24, 25). Since the bond
lengths for Hg(II) complexes of HAHl are different, from 2.34 Â, the partial NQI for
mercury(II) thiolate has been scaled (Table 6.2).
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Table 6.2: Calculated partial NQI for Hg(II)HAHl .
Ligand

Bondlength

partial NQI

Cysl2A

2.3

0.753

Cysl5A

2.5

0.586

Cysl2B

2.5

0.586

Cysl5B

2.8

0.417

[A]

[GHz]

The BASIL calculations based on X-ray structure of HAHl predict the PAC
parameters that compare well with the experimental constraints of trigonal complexes
for a fit with low ? as well as with experimental parameters for distorted tetrahedral

complex where high ? has been fitted (Table 6.3). Thus, the predicted PAC
parameters actually agree fairly well with the experimental data, but either of the two
options may be the correct structural interpretation of the PAC data.
Table 6.3: NQFs parameters calculated from the X-ray structure.
Structure

Vq[GHz]

Threecoordination

0.668

0.276

Fourcoordination

0.602

0.529

Information from 199Hg NMR and 199mHg PAC allowed us to elucidate the pH
dependency of coordination properties of HAHl. At the physiological pH, Hg(II)
forms, in solution, a preferred digonal HgS2 form. While pH increases binding of
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further thiolate ligand(s) is observed. Both techniques point to a 4-coordinate
environment, and the PAC data suggests it is a distorted 4-coordinate environment.

To further support the findings of the previous two techniques UV-Vis spectroscopy
measurements were performed to determine the metal to ligand charge transfer bands

for mercury(II) thiolate coordination at the different pH values (Figure 6.3). The
presence of the ligand to metal charge transfer band at 278 nm (e = 23100) indicates

the formation of HgS4 rather than HgS3 complex, further corroborating the
mercury(H) NMR data (26).
3.On
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Figure 6.3: Electronic difference spectra of Hg(II) complexes of HAHl with
changes in pH.
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6.4

Aggregation State Studies Based on pH Titrations Using Gel
Filtration Analysis

One final experiment was performed to determine the aggregation state of the
Hg(II)HAHl. This information would determine whether the different coordination

species exist as monomers or dimers. To do this high resolution gel filtration studies
were done to determine apparent masses. Figure 6.4 shows the elution profiles at
five different pH values.

As the pH increases so does the mass, indicating

aggregation or dimerization.

Table 6.4: Compilation of the elution volumes and apparent masses OfHg(II)HAHl
at the various pH values.
J)H1,
7.5
8.5
9.4
9.8
10.2

Elution Volume, mL:

Apparent Mass, kDa:

_______15.3
_______15_?
_______14.2
_______14.5

______6J
______7J
_______15^5

14.0

14.5
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_______13.0

Hg(M)HAHI pH 7.5

Hg(II)HAHI pH 8.5
Hg(II)HAHI pH 9.4
:

f
?
e
p
.a

40

Hg(II)HAHI pH 9.8

Hg(II)HAHI pH 10.2

?
IO

<

Elution Volume, m L

Figure 6.4: Hg(II)HAHl high resolution gel filtration curves showing the elution

profiles.from a superdex 75 10/30HR column (pH range 7.5-10.2). It is evident that
there are higher aggregation states at higher pH.

apoHAHl pH 7.5
apoHAHl pH 8.5
apoHAHl pH 9.4
apoHAHl pH 9.8
apoHAHl pH 10.2

14

15

16

Elution Volume, mi-

Figure 6.5: apoHAHl high resolution gel filtration curves showing the elution
profiles from a superdex 75 10/30HR column (pH range 7.5-10.2). It is evident that
there are higher aggregation states at higher pH, most likely controlled by
electrostatics due to the basic nature of the solution.
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Table 6.4 shows the apparent masses of each of the metal-bound species. At pH 7.5
the mass clearly indicates a monomer, as does the mass at pH 8.5. In the NMR data

there was strong evidence for two different species existing at the latter pH, however
due to the conditions of the gel filtration study two peaks were not observed. As the
pH was increased there was clear indication the HAHl had homodimerized as the
mass was approximately twice the monomeric mass. As the pH is increased the

proteins become more negative. At the highest pH value it is starting to become basic
enough to pull the proton off tyrosine groups (pKa approximately 10), so
electrostatics play a large role in controlling the environment around the mercury(II).
This was evident in the apoHAHl titrations done the same as the Hg(II)HAHl gel
filtration studies (Figure 6.5).
6.5

Conclusion

The crystal structure of the Hg(II)HAHl dimer showed at least a 3-coordinate
structure, but there seemed to be a distorted fourth coordinate.

It wasn't clear

whether this was fourth ligand because it wasn't close enough to be a covalent bond
to the metal. It was not until this work that PAC was used to determine if the fourth

ligand was close enough to be coordinated to the mercury(II). Analysis of the PAC
data indicated the possibility of two different species based on model fitting, 3- or
distorted 4-coordinate. The distorted 4-coordinate model fit better to the data and was

considered to be the symmetry exhibited by the Hg(II)HAHl.

The NMR data and aggregation state data seem to only give clues as to
changes based on pH differences. The NMR data corroborated with the mercury(II)164

199m PAC experiments where at low pH, there was only one species and it was
definitely 2-coordinate based on previous work by the O'Halloran group on the
ATXl protein (22). They found the 2-coordinate Hg(II)ATXl protein exhibited a
peak at -821ppm which is very close to the chemical shift in this experiment, -819
ppm (22). As the pH was increased there was a second peak that emerged (-348
ppm). This chemical shift correlated to a range where 4-coordinate mercury(II)
thiolates exist, but doesn't give any information as to the geometry of the complex.
Finally, the highest pH showed a single peak at the new chemical shift.

Along with these biophysical measurements, it was important to look at the
aggregation state of the Hg(II)HAHl. Once the coordination is known, it was

necessary to understand if there was a dimer throughout the pH range studied, or if
there was initially a monomer and then the pH increases made the environment such
that dimers were favored. The latter is true in this case, at low pH the apparent mass
was 6.8 kDa, but as the pH was increased the apparent mass increased. The apo
proteins apparent mass was also determined using the gel filtration analysis. The
masses of the apo compared to holo proteins didn't change dramatically, indicating
that the pH increases are more conducive to forming dimers. This would be expected
because the higher the pH the more negative the protein becomes and brings into play
more electrostatic interactions.

These experiments showed the Hg(II)HAHl can form a dimer at higher pH,
but this isn't such a physiologically relevant experiment. In the crystal structure of
the dimerized Hg(II)HAHl is a lowest energy structure, however this may not be
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indicative of the state of the complex in solution. Accordingly, near physiological pH
the protein behaves as a monomer with a 2-coordinate Hg(II) thiolate environment.
This work has shown Hg(II)HAHl could support a distorted 4-coordinate dimer, but

seems unlikely that it would in a physiological environment. Further, as the pH was
increased, there was a higher likelihood for aggregation.
6.6

Significance of Study

These experiments probed the environment around the mercury(II) as it bound
to HAHl. It is important to note however that physiologically, only a 2-coordinate
monomer existed. The relevance of the titrations outside physiological pH was to
corroborate relevance of a crystal structure of the Hg(II)HAHl dimer. Even though
the dimer may not exist physiologically, it does give information as to the effect of

local changes to the protein, and provides a model for other 4-coordinate species. It
was also a probe to further indicate the usefulness of PAC as a method for
determining coordination geometries and symmetry.
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